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Effectiveness of interventions to
improve the identification and reporting
of medication-related patient safety
incidents in primary care: a systematic
review
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School of Pharmacy, University of Nottingham
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Medication-related patient safety incidents (MRPSIs)
cause a significant burden on healthcare resources. Pre-
vious work looking at MRPSIs from primary care has
highlighted how poor reporting of incidents makes anal-
ysis and subsequent learning challenging [1]. Improving
the quality of MRPSIs reporting has been recommended
to enhance the ability to identify learning for healthcare
systems improvement.
The aim of this systematic review is to identify, sum-
marise and describe the evidence of effectiveness of
interventions aimed to improve the identification and
reporting of MRPSIs in primary care.
A protocol for the systematic review was registered
with the PROSPERO international prospective register
of systematic reviews (CRD42017049676). Narrative
synthesis of randomised controlled trials (RCTs) was
conducted to assess the effects of professional and
organisational interventions in comparison to the exist-
ing system of usual practice or no comparison to
improve the identification and reporting of MRPSIs in
primary care. Database searches were conducted using:
Ovid MEDLINE, EMBASE, IPA, PsycINFO, and
EBSCO CINAHL. Studies where the outcome measures
included interventions to improve the number of MRPSIs
identified and/or reported and the quality of reports were
included. Titles and abstracts were assessed against the
inclusion criteria. Then, full-text of the studies retrieved
and assessed independently by two reviewers. Method-
ological quality was appraised independently by two
reviewers using Cochrane Collaboration criteria [2].
Five RCTs met the inclusion criteria and all were
conducted in general practice. Three of the RCTs identi-
fied and corrected MRPSIs using the process of feed-
back to prescribers with other adjacent complex
intervention components. These RCTs used electronic
patient medical records to identify patients at risk of
unsafe prescribing. The RCTs demonstrated a notable
reduction of high-risk prescribing of selected medicines
ranging from 12% to 37% in intervention arms. The
harm reduction observed was attributed to improved
identification and reporting of MRPSIs. The other two
RCTs reported complex interventions encompassing use
of a validated patient safety culture questionnaire with
other adjacent complex intervention components. The
RCTs showed improved frequency of patient safety inci-
dents. Two studies reported high quality trials due to
adequate reporting of randomisation but all the five
studies were judged low quality overall due to high risk
of performance bias. All trials were conducted between
2012 and 2016 demonstrating a recent evidence of pri-
mary research investigating the effects of complex inter-
ventions to improve MRPSIs identification and
reporting.
Evidence shows effectiveness of using complex inter-
ventions for the identification or reporting of MRPSIs
in primary care. Evidence also shows that using patient
medical records is an effective method to identify and
encourage reporting of MRPSIs. Organisational culture
is an important determinant of effectiveness of incident
reporting systems. Achieving patient-centred, safe and
effective use of medicines is coupled with applying the
principle of a just culture in healthcare organisations.
Due to the limited number of studies included, varied
outcome measure definitions employed, findings should
be interpreted with caution for different contexts.
References
1. Muhammad, K.W., Avery, A.J., B, M.J. and Carson-
Stevens, A., 2016. Medication safety incidents
reported to the National Reporting and Learning
System in England and Wales: a review of primary
care incidents classified as severe harm and death
International Journal of Pharmacy Practice. 24(Sup-
plement 3), 0108.
2. Effective Practice and Organisation of Care (EPOC).
2015. Suggested risk of bias criteria for EPOC
reviews. EPOC Resources for review authors
[Online]. Oslo: Norwegian Knowledge Centre for the
Health Services. Available: http://epoc.cochrane.org/
epoc-specific-resources-review-authors [Accessed 3/5/
2016].
ª 2018 The Authors. IJPP ª 2018 Royal Pharmaceutical Society International Journal of Pharmacy Practice, 26 (Suppl. 1), pp. 4–36
4 International Journal of Pharmacy Practice 2018; Supplement 1
A systematic review of practical tools or
frameworks to help deconstruct safety
incidents and learn from them
N. Seroua,b,c, L. M. Sahotaa, A. K. Husbanda,
S. P. Forresta, K. Moorthyb and S. P. Slighta,d,e
aSchool of Pharmacy, King George VI Building, Newcastle University,
Newcastle upon Tyne, UK bTheatres and Anaesthetics, Imperial
College Healthcare NHS Trust, UK cCollege of Nursing, Midwifery and
Healthcare, University of West London, UK dNewcastle upon Tyne
Hospitals NHS Foundation Trust, Queen Victoria Road, Newcastle
upon Tyne, UK and eThe Centre for Patient Safety Research and
Practice, Division of General Internal Medicine, Brigham and Women’s
Hospital and Harvard Medical School, Boston, MA, USA
n.serou2@newcastle.ac.uk
According to the National Reporting and Learning System
recent report, 1,798,186 patient safety incidents occurred
between July 2015-June 2016.1 Organisations should learn
from these safety incidents so similar events do not occur
in future. A number of tools and initiatives were used
within industry to learn from safety incidents, some of
which could be adapted and used in health care.
The aim of this study was to explore what practical
tools are currently available to help multi-disciplinary
teams deconstruct and learn from safety incidents.
This review followed the PRISMA-P reporting guideli-
nes and was registered with the PROSPERO database
(CRD42017071528). We defined a practical tool as either
a tool, learning process or approach used to learn from
safety incidents. We defined a safety incident as any
unplanned or undesired event that hindered the comple-
tion of a task and may have caused injury or illness.2 We
generated a list of MeSH terms and text words, with
expert input from the University librarian. We searched
MEDLINE, EMBASE, CINALH, PsycINFO, SCOPUS,
Web of Science and ProQuest in June 2017. Doctoral
dissertations and conference proceedings identified in
the grey literature (http://www.opengrey.eu), and reports
from National Patient Safety Agency, and Local and
Regional Clinical Commission Groups were also
reviewed. We included primary research studies or
reviews that described a practical tool used previously in
any sector e.g., healthcare, mining industry, aviation,
energy, construction companies etc. A customised data
extraction form was used to capture pertinent informa-
tion from included studies and the CASP tool to appraise
their quality.
A total of 4,724 articles were identified, with 942 dupli-
cate articles removed and 3,759 excluded at the title (825),
abstract (2,524) and full text (410) stages. Twenty-three
articles were included in the final review (22 full text stud-
ies and one review). Six practical tools were found and
four key themes emerged: (1) Debriefing, (2) Simulation
training, (3) Usage of technology, (4) Dissemination of
safety incidents. Debriefing was one method used to help
staff to deconstruct incidents and learn as a team. One
such tool included in the debriefing was the After Action
Review model, which centred on four questions: What
was expected to happen? What actually occurred? What
went well and why? What can be improved and how? The
Aviation industry used trained psychologists to facilitate
debriefing sessions, which were mandatory for staff to
attend. Studies have suggested that the timing, facilitation
and consistency of debriefing was essential to maximise
learning. All tools highlighted in the literature had pros
and cons depending on the sector in which they were
applied. Simulation training involved asking staff to relive
the event again by performing the task(s) in a role play,
and sharing the learning and recommendations following
an incident. The use of e-learning and safety apps were
also recommended as a way of disseminating key safety
messages, although some messages were not actioned due
to poor leadership and governance.
Each practical tool had pros and cons. The timing,
facilitation and consistency of debriefing were essential
to maximise learning. Organisations should be encour-
aged to use practical tools to help staff learn from safety
incidents
We excluded studies that focused solely on learning
theories and barriers to learning from incidents. These
studies may provide further insights and recommenda-
tions for prospective learning tools.
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The use of multiple medications (polypharmacy) in older
people (>65 years) is common clinical practice and
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increasingly recognised as potentially problematic rather
than always inappropriate. Accordingly, assessments of
prescribing appropriateness needs to differentiate between
‘many’ medicines (appropriate polypharmacy) and ‘too
many’ medicines (inappropriate polypharmacy).[1] Select-
ing the most effective interventions to ensure appropriate
polypharmacy in older people remains challenging.
The aim of this Cochrane review was to determine
the effectiveness of interventions seeking to improve
appropriate use of polypharmacy in older people, by
updating the review which was published in 2014.[2]
A systematic review was undertaken using standard
Cochrane methodology. A range of electronic databases
(e.g. EMBASE, MEDLINE) were searched for articles
published between November 2013 and May 2016 using
relevant search terms (e.g. ‘polypharmacy’, ‘inappropri-
ate prescribing’) as per original review.[2] Eligible studies
(randomised controlled trials, non-randomised con-
trolled clinical trials, controlled before-and-after studies,
interrupted time-series studies) evaluated interventions
aimed at improving appropriate polypharmacy in older
people, using validated measures of prescribing appro-
priateness [e.g. Beers criteria, Medication Appropriate-
ness Index (MAI)]. Primary outcomes of interest were
changes in the prevalence of appropriate polypharmacy
and hospital admissions. Secondary outcomes included
medication-related problems (e.g. adverse drug reac-
tions). Two review authors independently screened
abstracts, extracted data and assessed risk of bias for
included studies. Study-specific estimates were pooled
for explicit/criterion-based measures (e.g. Beers) and
implicit/judgement-based measures (e.g. MAI) of pre-
scribing appropriateness using a random-effects model
to yield summary effect estimates and 95% confidence
intervals (CIs). The GRADE approach was used to
assess the quality of evidence for pooled effect estimates.
Ethical approval was not required.
Eight studies were added to the review bringing the
total number of included studies to 20, involving 25,674
participants. Two interventions involved computerised
decision-support and the remainder comprised complex
pharmaceutical care-based interventions across various
clinical settings. Changes in medication appropriateness
scores using implicit tools showed a greater reduction in
inappropriateness between baseline and follow-up in
intervention groups compared to control groups (mean
difference -6.34, 95% CI -12.23, -0.45). Assessments of
the number of potentially inappropriate medications
(PIMs) and potential prescribing omissions (PPOs) using
explicit tools showed fewer PIMs (standardised mean dif-
ference -1.06, 95% CI -2.01, -0.12) and fewer PPOs per
participant (standardised mean difference -0.81, 95% CI -
0.98, -0.64) in intervention groups compared to control
groups post-intervention. The proportion of patients pre-
scribed ≥1 PIM (relative risk 0.61, 95% CI 0.42-0.89) was
lower in intervention groups compared to control groups
post-intervention. The overall quality of evidence for all
pooled outcomes was low or very low. Evidence of the
effects of interventions on hospital admissions and medi-
cation-related problems was conflicting.
This updated review found that included intervention
studies reduced inappropriate prescribing for older peo-
ple receiving polypharmacy. However, the quality of evi-
dence from pooling data across studies remains weak. It
is also still unclear whether interventions resulted in
clinically significant improvements for patients. Future
intervention studies could benefit from available guid-
ance relating to intervention development, evaluation
and reporting.
This work was supported by the Health Research
Board [grant number: HRC/2014/1].
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Intervention studies seeking to improve appropriate
polypharmacy (≥4 medicines) in older people (≥65 years)
often differ in reported outcomes, making it challenging
to synthesise results.[1] To address this, the Core Out-
come Measures for Effectiveness Trials (COMET) initia-
tive has proposed the development of a core outcome
set (COS).[2]A COS is an agreed, standardised outcome
set which should be measured and reported, as a mini-
mum, in all trials in a specific clinical area. The
COMET initiative also recommends involving public
participants in COS development, facilitating a move
away from researcher-only selected outcomes.[2]
This study aimed to develop a COS for use in effec-
tiveness trials of interventions aiming to improve appro-
priate polypharmacy in older people in primary care.
Standard COS development methodology was fol-
lowed, comprising: (1) an update of an existing Cochrane
systematic review[1]; (2) identification of outcomes from
previously collected qualitative data, and; (3) an online,
three-round, Delphi consensus exercise. An international
expert panel (n = 120) and a public participant panel
(n = 40) were recruited for the Delphi exercise. Expert
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panellists included those with knowledge relevant to the
COS (e.g. general practitioners, pharmacists, research-
ers). Public panellists included older people who were res-
ident in the community. Identified outcomes were scored
on a 9-point Likert scale using the GRADE scoring sys-
tem anchored between 1 (not important) and 9 (critical).
Consensus criteria for outcome inclusion were defined as
≥70% of participants scoring the outcome as ‘critical’
and ≤15% scoring the outcome as ‘not important’. The
seven highest ranked outcomes were also identified in line
with COMET recommendations.[2] The study was
approved by the School of Pharmacy Ethics Committee,
Queen’s University Belfast.
Twenty-nine outcomes identified from updating the
Cochrane review and existing qualitative data were
included in the Delphi exercise. After three Delphi
rounds, which were completed by 152, 140 and 127 par-
ticipants respectively, the final COS comprised 16 out-
comes, with priority given to the seven highest ranking
outcomes: ‘serious adverse drug reactions’, ‘medication
appropriateness’, ‘falls’, ‘medication regimen complexity’
‘quality of life’, ‘mortality’ and ‘medication side-effects’.
The remaining nine outcomes were: ‘hospitalisations’,
‘patient’s knowledge’, ‘adherence’, ‘clinically significant
drug interactions’, ‘number of regular medicines pre-
scribed’, ‘therapeutic duplication’, ‘prescribing errors’,
‘cognitive functioning’ and ‘patient perception of treat-
ment (or medication) burden’.
This work has identified 16 outcomes, which should
be considered for inclusion in effectiveness studies aimed
at improving appropriate polypharmacy in older people
in primary care. We recognise that having many out-
comes may be impractical. Therefore, in line with
COMET recommendations, we have highlighted the
seven highest ranking outcomes. We suggest that these
seven outcomes should be priority outcomes, with the
remainder considered depending on the specific interven-
tion and theoretical underpinning. The value of public
participants’ involvement was evidenced in the final Del-
phi round whereby the outcome ‘patient’s knowledge’
would not have been included if the panel only comprised
experts. Implementation of this COS may benefit patients
and healthcare providers by facilitating evidence synthe-
sis. Future work should determine the most appropriate
methods of measuring each included outcome.
This work was supported by the Health Research
Board [grant number: HRC/2014/1].
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There have been concerns that antipsychotics have been
overused in people with intellectual disabilities (ID), and
may be prescribed inappropriately for behaviours that
challenge (BWC) in the absence of diagnosed mental ill-
ness. In addition, as people with ID live longer, they are
exposed to additional risks associated with antipsychotic
use in older adults (>40 years) including; frailty, cogni-
tive decline and mortality.
Determine the prevalence of exposure to antipsy-
chotics and antipsychotic polypharmacy (concurrent use
of 2+ antipsychotics) among older adults with ID.
Examine the patterns of antipsychotic utilisation
(typical/atypical).
Examine the association with antipsychotic use and
demographic and clinical characteristics including diag-
noses, BWC and concurrent use of medicines that act
on the CNS.
Data for this cross-sectional study was drawn from
Wave 2 (2013/2014) of the Intellectual Disability Supple-
ment to the Irish Longitudinal Study on Ageing (IDS-
TILDA); a nationally representative longitudinal study
which examines the ageing of persons over 40 years with
ID. Medication data (self/proxy report) was available for
95.6% (n = 677) and antipsychotic usage was determined
by the World Health Organisation (WHO) Anatomical
Therapeutic Index Code N05A. Antipsychotic polyphar-
macy was defined as use of 2+ antipsychotics.
To examine antipsychotic use and indications those
who reported hallucinations/psychosis/schizophrenia
were grouped together to describe those with a psychotic
disorder and manic depression was included as a
licenced indication for AP use (n = 73). BWC were also
reported in the study, as were other diagnosed mental
health conditions. Bivariate analysis was employed to
examine associations between antipsychotic use and
demographic and clinical characteristics including men-
tal health conditions and BWC, a P-value of <0.05
being considered significant.
Of the total population (n = 677), 45.1% (n = 305)
were exposed to antipsychotics and of those exposed
20.7% (n = 63) were exposed to antipsychotic polyphar-
macy. Risperidone was most frequently reported: 36.1%
(110) of those exposed to antipsychotics, followed by
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olanzapine 31.5% (96) and chlorpromazine (55, 18.1%).
Of 282 adults with antipsychotic use and diagnosis
information, 25.9% (73) reported a psychotic disorder,
57.4% (162) another mental health condition, 8.5% (24)
no mental health condition but BWC and 8.2% (23) no
mental health conditions or BWC. There was a signifi-
cant association (P < 0.001) between exposure and place
of residence; 54% (149) of those in institutional settings
exposed compared to 45% (135) in community group
homes and 20.6% (21) who lived independently. Having
severe/profound ID (P = 0.03), and reporting a doctor’s
diagnosis of a mental health condition (P < 0.001) and
reporting behaviours that challenge (P < 0.001) were
significantly associated with use. Among those reporting
antipsychotic polypharmacy, 60.3% had concurrent
antiepileptics, compared to 48.1% of those with one
antipsychotic (P < 0.001).
Over four in ten of older adults with ID in the study
were exposed to antipsychotics. The reported use of
antipsychotics significantly exceeded reported doctor’s
diagnosis of psychotic conditions or manic depression.
As study limitation was that the mental health condi-
tions and medication information was based on self-
report and/or proxy report. These findings highlight the
importance of medication review to prevent inappropri-
ate prescribing of antipsychotics.
A methodological study describing the
development of the Rationalising
Antipsychotic Prescribing in Dementia
(RAPID) intervention using the
behaviour change wheel, with public
and patient involvement
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Antipsychotic prescribing in care home residents with
dementia is prevalent despite the known harms and min-
imal benefits.[1] Many interventions have been shown to
be effective at reducing inappropriate antipsychotic pre-
scribing in this population in the short term, however
there is a lack of evidence to support the sustainability
of effects. There is a need to design an intervention
based on best available evidence and appropriate theory
to address this implementation issue. The Behaviour
Change Wheel (BCW) is an approach for applying
behavioural theory to intervention development.[2] Fur-
thermore, involving carers and people with dementia in
research, through their expertise by experience, helps to
ensure that the research is relevant to them, and can
also provide the researchers with unique perspectives.
The aim of our methodological study was to describe
the development of an evidence-based, theoretically-
informed intervention to improve the appropriateness of
antipsychotic prescribing in care home residents with
dementia, using the BCW approach, with Public and
Patient Involvement (PPI) throughout.
Ethics approval was granted by the local ethics com-
mittee. Written informed consent was provided for partic-
ipation in the semi-structured interviews and for
involvement on the advisory groups. Two advisory
groups were established, one with people with dementia,
and the other with carers. The advisory groups provided
insights into living with dementia, and caring for someone
with dementia including managing behavioural symp-
toms. Stakeholder discussions also occurred with GPs
and nurses to inform development of the intervention.
Following the three BCW stages, we sought to (1)
understand the behaviour, (2) identify intervention
options and (3) identify content and implementation
options. To understand the behaviour, we conducted a
systematic review of qualitative evidence (n = 18 studies),
and a semi-structured interview study (n = 27 partici-
pants) using the Theoretical Domains Framework. To
identify the intervention options that we believed would
most likely have the potential to change behaviour, we
utilised the APEASE (affordability, practicability, effec-
tiveness, acceptability, side effects and equity) criteria,
with advisory and stakeholder input. To identify content
and implementation options, we initially created a long
list of potential Behaviour Change Techniques (BCTs)
using various methods and a consensus activity to decide
upon a definitive list. We looked at the evidence, and dis-
cussed with stakeholders to determine the most effective,
practicable and acceptable mode of delivery.
We identified appropriate requesting and appropriate
prescribing of antipsychotics by care home staff and
GPs respectively, as our target behaviours. Ultimately,
we combined five intervention functions and opera-
tionalised 12 BCTs to form the Rationalising Antipsy-
chotic Prescribing in Dementia (RAPID) intervention.
The RAPID intervention is delivered using face-to-face
education and training with care home staff, educational
outreach with GPs and an assessment tool within the
care home environment.
This study successfully incorporated the voice of peo-
ple with dementia and carers into the development of a
complex intervention, however challenges existed with
regards to their involvement as co-researchers. The
RAPID intervention is currently undergoing feasibility
testing with a view to evaluating the effectiveness of the
intervention in a future randomised controlled trial.
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Clinical practice placements aim to provide learning
opportunities in which students can apply knowledge
and skills in a ‘real-life’ setting in order to increase pre-
paredness to provide patient-centred care in today’s
evolving healthcare environment.1,2
The aim of this research was to investigate MPharm
student perceptions of community pharmacy placements
and how effective they are at preparing students for
clinical practice.
A full cohort of MPharm students (n = 860) were
invited to complete an online questionnaire exploring
their opinions towards practice placement provision
within community pharmacy. The design of the ques-
tionnaire was informed via thematic analysis of a focus
group held with a representative sample of MPharm stu-
dents, wherein the research question evolved. The ques-
tionnaire was disseminated to all students via the
University’s Virtual Learning Environment over a 2-
week period.
Anonymous responses were collated electronically
and statistically analysed via SPSS V22. Response fre-
quencies within the questionnaire were collated to allow
analysis of student perceptions and to identify key
themes. Chi-squared statistical comparisons (Cramer’s V
test) were made between responses.
Free text responses were thematically coded and
analysed.
The questionnaire generated a 95% response rate
(n = 816).
The predominant perception of placements was posi-
tive: 80.8% of respondents agreed or strongly agreed
that the majority of in practice pharmacist supervisors
are enthusiastic and well prepared, while 78.3% believed
placements had provided them with a valuable learning
experience. Negatively 82.4% agreed or strongly agreed
that if they had to undertake their pre-registration year
with solely experience from placements, they would
struggle.
There were statistically significant associations
between the benefits of placements and student experi-
ence to date (including the year of study and previous
pharmacy work experience). Those students with self-
arranged work experience found placements organised
by the University less beneficial.
Free text responses supported this, students com-
mented that they often felt out of place and unable to
get involved in busy pharmacy environments; this was
especially true for students in early years of study or
those without previous work experience. These students
had also completed fewer placements than those in
higher levels at the point of data collection, which may
have limited the variety of their experiences.
Work-based learning through clinical practice place-
ments is an essential part of the education and training
of pharmacists.1,2 However community pharmacy envi-
ronments are often busy and unpredictable. Students
from lower stages or without pharmacy experience com-
mented that they felt unable to get involved, particularly
in busy workplaces. It is reasonable to suggest that com-
munity pharmacy sites with lighter workloads may be
better suited to students without prior experience,
enabling more contact time with supervisors.
Educators should note that community pharmacy
placements are clearly beneficial in shaping student under-
standing of the role of the pharmacist in clinical practice.
However this research demonstrates that students feel
that aspects of community pharmacy placements could be
improved, which in turn would help to prepare them more
effectively for future clinical professional careers.
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Advances in paediatric medicine, increasing complexities
of childhood disease, and unique dosing and pharma-
cokinetic challenges all support a growing need for the
education of pharmacists in basic paediatric competen-
cies. This is quite important specifically with the high
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prevalence of unlicensed and off-label medicine use in
children.
The present study aims to explore the perception and
attitudes of final year pharmacy students toward their
ability to deal with paediatrics, their treatment, and
their doses.
The questionnaire was developed after an extensive
literature review of studies that assessed healthcare pro-
fessionals’ knowledge of paediatrics. The questionnaire
was assessed for face and content validity by being sent
to a panel of experts in the field of paediatrics, pharma-
ceutical care, and quantitative studies. The questionnaire
was the piloted among 20 final year pharmacy students.
Those were not included in the final analysis.
After obtaining the required administrative and ethi-
cal approvals, the questionnaire was administered to
final year pharmacy student’s at all ten faculties of phar-
macy in Jordan. The questionnaire was administered at
the end of lectures that were chosen by the faculty’s
administration.
The questionnaire consisted of 28 questions and was
divided into four sections; the first section collected
respondents’ demographics, while section two aimed at
exploring respondent’s knowledge of paediatric treat-
ment and dosing. The third section of the questionnaire
explored respondents’ perceptions of their ability to deal
with paediatric treatment and dosing. The fourth section
consisted of real life paediatric cases to assess the real
ability of respondents to deal with paediatric patients.
A total knowledge score was calculated by summing
the correct answers creating a scale of zero to five,
where 5 is the highest knowledge score and zero was the
lowest knowledge score.
Of 400 students approached 354 (88.5%) students
agreed to take part in the study. The majority of
respondents (n = 337, 95.2%) were aware of the term ‘
paediatrics ‘. Up to one third of respondents (n = 108,
30.5%) reported not coming through any paediatric
dose calculation courses during their education and
more than half the respondents (n = 197, 55.6%) were
not familiar with the term off-label medicines and have
not come across it during their education. Respondents
were doubtful and not sure that they will be able to rec-
ommend treatment for paediatrics (n = 120, 33.9%), cal-
culate paediatric doses (n = 142, 40.1%), counsel
parents of guardians (n = 159, 44.9%), and monitor side
effects in paediatrics (n = 255, 72.0%).
The majority of respondents had a low knowledge
score when faced with real-life paediatric cases. On a scale
of five 46 (13%) respondents scored zero, 120 (33.9%)
respondents scored one, 100 (28.2%) respondents scored
two, 74 (20.9%) respondents scored three, and 12 (3.4%)
respondents scored four, and only 2 (0.6%) respondents
scored 5. No significance difference in knowledge and
attitude was found between pharmacy (BSc) or PharmD
students nor public or private university students.
The present study sheds the light on the importance
of increasing the paediatric content in the pharmacy cur-
riculum adopted by Jordanian Universities. Pharmacy
students should take more formal paediatric education
and extensive training in paediatrics to be able to deal
with paediatrics and their treatments.
The current situation may have negative effects on
pharmaceutical care in children. Prompt and direct action
should be taken to develop paediatric pharmacy educa-
tion and to enhance paediatric pharmaceutical care.
Though they were informed about the anonymity of
the study and the freedom to take part in it; the data
collection method through classes could have affected
the way respondents answered the questionnaire in
terms of feeling obliged to complete the study.
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In the UK, unplanned hospital admissions (UHAs)
related to Chronic Obstructive Pulmonary Disease
(COPD) are a major burden on the NHS. While medi-
cation can reduce UHAs,[1] little is known about the
role of patients’ social networks in supporting medici-
nes-taking. This study aimed to describe the activities
and strategies recently discharged COPD patients utilise
to manage their medicines, and identify the social net-
work members (SNMs) involved.
Semi-structured, face-to-face interviews (aver-
age = 39 min) with COPD patients recently discharged
from an acute NHS Trust in the Northwest of England
between March and August 2016 were conducted,
audio-recorded and transcribed verbatim with consent.
Maximum variation sampling was used based on gen-
der, disease severity, and discharge pathway. The topic
guide and coding framework were informed by
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Cheraghi-Sohi et al.’s[2] conceptual framework for ‘med-
ication work’ for coronary heart disease (CHD), arthri-
tis and diabetes, which identified four types: medication-
articulation, informational, emotional and surveillance
work. Data analysis was thematic and facilitated by
NVivo (v11). NHS ethical approval was obtained.
Seven males and five females, aged between 56 and
84 years, were interviewed. Participants’ social networks
were small (n < 5) and restricted to immediate family
members and healthcare professionals. Participants/
SNMs performed similar medication-articulation and
surveillance work to patients with CHD, arthritis and dia-
betes, the inter-dependence between which this study con-
ceptualised as surveillance-articulation, i.e. the need to
act on this information. Many participants described how
they/a family member organised/repackaged their medici-
nes; this was more burdensome for participants taking
higher numbers of medicines. Some participants
instructed their community pharmacy to assemble dosette
boxes monthly. These activities reduced the time required
to take medicines at dose times and helped participants
keep track of their progress within a day: pills in compart-
ments indicated medication was due, empty compart-
ments assured participants’ doses had been taken. Habit/
routine (including placing medicines in frequently visited/
visible locations within the home) were described as
important to patients/family carers with regards to know-
ing which medicines to take and when. Disruption to rou-
tines such as sleep disturbances and the addition of
midday doses impacted on participants’ ability to take
medicines at the prescribed times of the day. In some
cases, immediate family members helped maintain partici-
pants’ routines by reminding and supporting medicines-
taking at prescribed times. Waking/sleeping, meals, bever-
ages and the time of day reinforced these routines and
assured participants that they had taken the correct
medicines at the correct times. While some participants
consulted patient information leaflets to address informa-
tional needs; predominantly for new/recently changed
medicines, participants infrequently described informa-
tional work. Emotional work was also rarely described.
After discharge, participants commonly reverted to pre-
admission routines and strategies for obtaining medica-
tion supplies, organising medicines, keeping track of sup-
plies and progress within daily regimens, and monitoring
symptoms and prescribing/dispensing.
This qualitative study identified a fifth type of medica-
tion work, surveillance-articulation, which was performed
by participants/SNMs to resolve issues identified by
surveillance work. This study identified potential inter-
vention points to be addressed before and after hospital
discharge, with inter-dependence suggesting interventions
must address multiple types of ‘medication work’.
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Patient feedback questionnaires to
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professionals: a systematic review
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Practitioners are increasingly encouraged to seek feed-
back from their patients and colleagues in order to
enhance the quality of interactions(1). Previous system-
atic reviews of patient feedback were primarily focused
on physicians, therefore, this systematic review aims to
describe all the potential patient feedback questionnaires
available across all practitioners, and to identify their
key attributes.
The aim of this systematic review was to identify
patient feedback questionnaires that assess and enhance
the development of consultation skills (CSs) of individ-
ual practitioners.
A systematic search from inception to January 2017
was conducted using seven databases to identify patient
feedback questionnaires that met the following inclusion
criteria: self-completed by real adult patients, assess CSs
of practitioners following a face-to-face encounter and
where feedback results were used to develop CSs of indi-
vidual practitioners. Practitioners were considered if
their encounter with a patient was conducted as a com-
ponent of healthcare delivery. Studies were rejected if they
did not meet the inclusion criteria. Only quantitative
study designs were included; qualitative studies and
reviews were rejected. The review was Prospero registered
(CRD42017055365). Search results were restricted to jour-
nals written in English language. Results were checked
for eligibility by three authors and disagreements were
resolved by discussion. Reference lists of relevant studies
and Open Grey were searched for additional studies.
Authors of studies were contacted by email where neces-
sary for missing data. Studies with missing questionnaires
were rejected following failed attempts to contact authors.
As a systematic review, no ethical approval was required.
Of 16,312 studies retrieved, sixteen were included,
fourteen of which were cross sectional studies, one
quasi-experimental study and one randomised controlled
study. Twelve patient feedback questionnaires were
described and were mostly designed for physicians.
Studies required between six and fifty patients per prac-
titioner (PPP) (mean 28 patients), with eleven studies
requiring ≥25 PPP. Where reported, questionnaires were
administered by practitioners (n = 6), or by a third party
(e.g. receptionist) (n = 7). Most questionnaires had lim-
ited data regarding their psychometric properties, except
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for the Doctor Interpersonal Skills Questionnaire. Most
practitioners received individualised reports constructed
from their patient feedback. Most studies conducted fol-
low-up, capturing positive views of practitioners regard-
ing the process (n = 14). Three studies repeated the
feedback process more than once over varying time-
frames and all demonstrated improved patient feedback
over time.
This review followed a Cochrane Database of Sys-
tematic Reviews approach. Several patient feedback
questionnaires are available, showing potential for sup-
porting practitioners’ development. However, most iden-
tified questionnaires were focused on physicians, and
there is no evidence regarding their use with pharma-
cists. Questionnaires need to be validated with all practi-
tioners before evidence of their impact can be evaluated.
As with most included studies, for valid and reliable
results, feedback should be collected from at least 25
PPP (2), preferably immediately following the encounter.
Feedback results should be reported to practitioners and
follow-up should be carried out at regular intervals to
detect changes in CSs. Limitations encountered with this
review include rejecting studies with missing data (i.e.
missing questionnaire), and excluding non-English lan-
guage journals.
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Medicine reuse is the idea that unused prescribed medici-
nes returned by one patient to a pharmacy would be re-
dispensed for use by another – a practice not currently
permitted in the UK and for which public opinion
remains largely unexplored.
Having developed (1) and validated (2) a structured
questionnaire to capture people’s willingness to take part
in medicines reuse in the future, our aim was to dissemi-
nate the questionnaire via a market research company
(ResearchNow) to quantify the views of a cross section
of 1,000 patients in relation to medicines reuse.
Participants were recruited via an online platform
(Qualtrics) using purposive sampling to include only
those with a long-term condition requiring medication.
An internal pilot (10% of the total sample, n = 100) was
undertaken to review and quality-check data before the
full launch in September 2017. During data collection,
the representativeness of the sample was monitored for
geographical spread, age groups and gender balance but
no adjustment to the recruitment strategy was necessary.
Ethical approval was obtained via the in-school exemp-
tion process. Descriptive analysis was completed with
the anonymised dataset using SPSS (V23).
A total of 1,181 people were invited to complete the
questionnaire, with 178 excluded because they reported
not having a long-term condition, resulting in 1,003
valid responses. In line with census data, 50.7%
(n = 509) of respondents were female, 92.4% (n = 927)
were white British and the largest contribution was from
those aged 45–64 years (45.9%; n = 498).
Most participants thought reusing medicines in the
future would be beneficial (54%; n = 541) and worth-
while (59%; n = 591), would contribute toward reducing
the harmful effect of medicinal waste on the environ-
ment (74%; n = 742) and reducing NHS medicines
spend (79%; n = 792). This was juxtaposed with a belief
that medicines reuse was more likely to result in receipt
of low quality (58%; n = 582), unsafe (57%; n = 572),
or incorrect medication (60%; n = 602). Nonetheless,
more than half intended (55%; n = 552) or wanted
(57%; n = 572) to reuse medicines in the future with the
expectation that medicines offered for reuse would have
been subjected to safety (93%; n = 933) and quality
(92%; n = 923) checks, would remain in original sealed
blister packaging (87%; n = 873), with >6 months
remaining shelf-life (85%; n = 853).
It can be concluded that although people have con-
cerns about medicines reuse, the idea is not unpalatable
provided certain caveats are put in place. Research using
panels can be limited by issues relating, for example, to
whether members are representative of the target popu-
lation. This was addressed by using quotas and screen-
ing questions resulting in a representative sample.
However, the use of an online panel would have
excluded people with no internet access. The strength of
this research is that it captures viewpoints from a repre-
sentative sample of the UK patient population, provid-
ing robust evidence about patients’ beliefs and
intentions to take part in medicines reuse. The results
can inform any future policy on reducing medicines
waste through reuse in the future.
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Research on medication errors, and prescribing errors in
particular, has concentrated on the acute sector. Little
has been published on these issues in mental health,
where the frequency and nature of prescribing errors
may be different.
The aim of this study was to investigate the preva-
lence and types of prescribing errors in prescriptions for
inpatients in a mental health setting.
Data were collected by 14 pharmacists as part of
their routine duties on 25 wards, using methodology
previously used in acute hospitals,1 during two discrete
48-week periods chosen for convenience. The process
was piloted at one site, and face-to-face training pro-
vided to each pharmacist. Pharmacists screened newly
written prescription items using an established definition
of prescribing error, adapted for a mental health set-
ting.2 Data were collected on the number of newly pre-
scribed, or omitted items, and the corresponding
number of errors identified. Pharmacists assessed the
potential clinical significance of each error using a visual
analogue scale, and were validated by a multi-disciplin-
ary panel of experienced healthcare professionals. Ethi-
cal approval was obtained from the University of
Portsmouth Science Faculty Ethics Committee.
During the two periods, 13,684 prescription items
were reviewed for errors or omissions. At least one error
was identified in 690 items, of which 60 were excluded
as not meeting the error definition, giving an overall
error rate of 4.6% (95% CI 4.3–4.9%). Fifty-nine pre-
scription items were affected by two errors, and 19 by
three errors, resulting in a total of 727 errors. Prescrip-
tions were written by 208 individual prescribers; nearly
two-thirds made at least one prescribing error (64.0%).
Errors most commonly involved incorrect administra-
tion times/frequencies (22.3%), strengths or doses
(19.5%), and formulations (17.3%). Omission of a medi-
cine from the prescription accounted for 8.1% of errors.
Pharmacists recorded an opinion on the clinical signif-
icance for 91.5% of the errors identified. Of these, 4.1%
were classified as potentially severe errors, and 28% as
potentially moderate errors. Three errors were judged to
have resulted in actual patient harm (0.4%). The number
of doses given or omitted before the error was identified
was provided for 78.8% of errors. The error was identi-
fied by the pharmacist and corrected before any doses
were administered in 61.1% of cases, and after only one
dose had been given in 10.6% of cases. In most cases,
the pharmacist resolved the error directly (47.0%),
contacting the prescriber in 27.3% of cases.
The overall error rate of 4.6% was lower than the
6.3% recently reported in a similarly designed study,
but higher than other studies in UK psychiatric hospi-
tals. The results reflected those of other studies which
found that only a small proportion of errors had the
potential to be serious, and most were promptly
resolved by pharmacy staff. Although this was a single-
site study and the finding may not be generalisable, it
had a large sample size.. The findings support the need
for regular clinical pharmacist involvement in mental
health wards where pharmacist input is frequently lower
than in acute settings.
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Benzodiazepine and Z-drug prescribing
in Ireland: a repeated cross-sectional
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Guidelines advocate that prescriptions for benzodi-
azepines should be limited to short-term use (i.e.
≤4 weeks) to minimise adverse outcomes (e.g. depen-
dence). However, guidelines are often not adhered to as
long-term benzodiazepine prescribing and use persists
worldwide. Long-term benzodiazepine use is potentially
inappropriate and can give rise to adverse effects includ-
ing cognitive and psychomotor impairment, particularly
in older people. Many countries have reported limited
or no significant reduction in benzodiazepine prescribing
levels in recent years. In some instances, changes in
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benzodiazepine prescribing have been offset by increases
in Z-drug hypnotic prescribing (i.e. zopiclone, zolpi-
dem).[1] However, the lack of evidence of any clinically
useful differences between both drug classes in terms of
effectiveness, potential for adverse effects, dependence
or abuse does not support Z-drug prescribing to reduce
benzodiazepine prescribing.[2]
This study aimed to examine prescribing rates and
secular trends for benzodiazepines and Z-drugs to
patients in Ireland using pharmacy claims dispensing
data available from 2005-2015.
This study involved a repeated cross-sectional analysis
of publically available pharmacy claims dispensing data
obtained from the General Medical Services (GMS) phar-
macy claims database maintained by the Health Service
Executive-Primary Care Reimbursement Services. The
GMS scheme provides free health services to people based
on means testing and age (those >70 years have higher
means thresholds). The sample comprised all GMS-eligi-
ble individuals aged ≥16 years from 2005-2015.
Prescribing rates per 1000 eligible GMS population
and 95% confidence intervals (CIs) were calculated for
each year. Duration of supply and rates of concomitant
prescribing of benzodiazepines and Z-drugs were deter-
mined. Age (16-44, 45-64, ≥65 years) and gender trends
were investigated. Negative binomial regression was used
to examine longitudinal trends in rates across years by
gender and age groups. P-values < 0.05 were deemed sta-
tistically significant. As the data were anonymised and
analysed at group level, ethical approval was not
required.
Benzodiazepine prescribing rates significantly
decreased from 225.9/1000 population (95% CI 224.9-
226.9) in 2005 to 166.1/1000 population (95% CI 165.4-
166.8) in 2015 (trend, P < 0.0001). Z-drug prescribing
rates significantly increased from 95.4/1000 population
(95% CI 94.7-96.0) in 2005 to 109.1/1000 population
(95% CI 108.6-109.7) in 2015 (P = 0.048). Approxi-
mately one third of individuals received long-term pre-
scriptions (>90 days) for benzodiazepines or Z-drugs.
The proportion of individuals receiving combinations of
benzodiazepines and Z-drugs increased from 11.9% in
2005 to 15.3% in 2015. Benzodiazepine and Z-drug pre-
scribing rates were highest for older women (≥65 years)
throughout the study.
This study provides the first detailed analysis of
national benzodiazepine and Z-drug prescribing trends
in Ireland using a large, high-quality dataset. Benzodi-
azepine prescribing to the GMS population significantly
decreased over time, and was coupled with significant
increases in Z-drug prescribing. The findings show that
benzodiazepine and Z-drug prescribing is common in
this population, with a third receiving long-term pre-
scriptions demonstrating the need for targeted interven-
tions to reduce potentially inappropriate long-term
prescribing and use. As the dataset represents approxi-
mately one third of the Irish population and is over-
representative of individuals with a lower socioeconomic
status, women and older age, definitive prescribing rates
for these medications remain to be determined.
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The EQUIP study [1] identified that foundation doctors
require training at induction on local practices. In
response to this a regional prescribing assessment was
created to enable trusts to identify weaker prescribers,
informing training and support delivered locally.
The aim of this study was to describe candidate per-
formance within the regional prescribing assessment for
newly qualified foundation doctors from 2012 to 2016.
This study was judged to be a service evaluation and
did not require ethical approval.
All foundation year 1 doctors on induction to acute
trusts, undertook the written assessment consisting of 5
scenarios to be answered using local drug charts and
guidelines. They were assessed by senior pharmacists and
doctors against a set of standard correct answers. The
results were collated. Content analysis was used to deter-
mine the nature of serious errors (SEs), which were sum-
marised for frequency of occurrence. An error rate was
calculated for each iteration of the assessment by divid-
ing the total number of SEs recorded by the total num-
ber of prescription scenario (5) and multiplying by 100.
A total of 2941 participants were included represent-
ing five cohorts in up to 15 NHS Trusts per year, full
results in Table 1. The majority of doctors had gradu-
ated from UK medical schools (95.7%). The assessment
has seen an increase in mean percentage scores by par-
ticipants since 2012 (66.2%) to 2016 (81.4%) but in con-
trast the total number of SEs scored within each cohort
has risen over the 5 years (237 – 924 in 2016) with the
maximum number of SEs made by a single participant
rising to 17 in 2016.
The limitations of this study were the lack of investi-
gation and consideration of the factors impacting candi-
date’s performance e.g. local resource (drug chart and
guidelines) and pre-assessment prescribing teaching vari-
ation.
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The results identified a need for the continuation of
an applied prescribing assessment upon induction, fur-
ther development of mechanisms to orientate doctors to
the prescribing systems locally on induction and genera-
tion of support systems to assist doctors who require
further development of prescribing skills.
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A shared electronic patient record (SEPR), and the
Summary Care Record (SCR) is available in England,
with community pharmacists (CP) access. In Ireland, a
SEPR is under development.
This research sought to:
Create an evidence-based conceptual framework to
inform the development of SEPRs.
Survey CPs in England and Ireland to describe their
views on SEPRs, based on the conceptual framework,
and generate recommendations to inform iterative devel-
opment.
A literature review was conducted, basic thematic anal-
ysis was applied and a conceptual framework was devel-
oped to inform questionnaire design. CPs were surveyed
in Ireland to assess readiness and willingness for SEPR
access and in England to learn about their experience of
SCR access and views on system implementation. The
survey sampling frame was CPs in Ireland and England.
Participants were recruited via email invitation and social
media containing a hyperlink to the anonymous question-
naires. Ethics approval was granted by the University.
Data were analysed using descriptive statistics, and cate-
gorical responses were compared using v2 test.
The conceptual framework identified four themes to be
addressed in SEPR development: Need, Design, Use and
Implementation. There were 201 responses in Ireland and
57 in England. As is common with online questionnaires
[1], the denominator was unknown and therefore response
rate could not be calculated. In Ireland, CPs identified the
need for access to patient information about medication
history (92%), allergies (92%), diagnoses (91%) and
rationale for therapy changes (91%). The most prevalent
expected barriers to accessing SEPRs for CPs in Ireland
were workload burden (66%), fear of litigation (51%)
and concerns about data security (48%).
CPs in England reported that training on SCR was
good or very good (59%) and the majority (71%) said it
was tailored to their role. Access to information through
SCRs was perceived to improve quality of care (92%),
Table 1 Assessment of demographic and participant performance
2012 2013 2014 2015 2016
Total Participants 415 524 557 753 692
Total Trusts 10 13 13 14 15
Participants with UK Medical Qualification (%) 96.4 96.2 97.4 93.2 96.2
Participants with Non-UK Medical Qualification (%) 3.1 3.6 2.1 4.8 3.5
Participants with Qualification not disclosed (%) 0.5 0.2 0.5 2.0 0.3
Mean score 22 24 27 26 28
Mean percentage score 66.2 74.93 76.84 80.26 81.4
Standard Deviation 14.8 11.46 11.82 10.11 10.8
UK Graduate Score Mean 66.8 74.4 77.1 81.8 82.3
Total number of Serious Errors made within assessment 237 392 795 912 924
Error rate 11.4 15.0 28.5 24.2 26.7
Maximum no. of Serious Errors made by a single participant 6 6 8 13 17
Average no. of Serious Errors per participant 1.49 1.61 2.03 2.22 2.21
Total participants with 0 Serious Errors 253 (61.0%) 281 (53.6%) 166 (29.8%) 343 (45.6%) 274 (39.6%)
Total participants making ≥1 Serious Errors 162 (39.0%) 243 (46.4%) 391 (70.2%) 410 (54.4%) 418 (60.4%)
Non-UK Medical Qualification with 0 Serious Errors 6 (46.2%) 4 (21.1%) 1 (8.3%) 9 (25.0%) 3 (12.5%)
Non-UK Medical Qualification making ≥ 1 Serious Errors 7 (53.8%) 15 (78.9%) 11 (91.6%) 27 (75.0%) 21 (87.5%)
UK Medical Qualification with 0 Serious Errors 247 (61.7%) 277 (55.0%) 165 (30.4%) 331 (47.2%) 271 (40.7%)
UK Medical Qualification making ≥ 1 Serious Errors 153 (38.3%) 227 (45.0%) 377 (69.6%) 371 (52.8%) 395 (59.3%)
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level of involvement in care (83%), service efficiency
(69%) and job satisfaction (63%). Reported improve-
ment in service efficiency was greater among frequent
users (91%) than infrequent users (50%), v2 (1, n = 34)
=7.95, P < 0.05. Medication history information in
SCRs was reported as being most useful. The speed of
accessing SCRs was reported as average or worse by
82%, with the majority (72%) in favour of write-access
being extended to users other than GPs.
A greater proportion of CPs in Ireland than England
indicated willingness to share information with other
community pharmacists (96% v’s 83%, v2 (1, n = 258)
=10.59, P < 0.05), hospital pharmacists (96% v’s 84%,
v2 (1, n = 258) =8.24, P < 0.05) and hospital doctors
(95% v’s 86%, v2 (1, n = 258) =4.30, P < 0.05).
SEPR design should consider the user interface and
experience, content of the record and access security.
There are many uses for CP access to SEPRs and initial
improvements may be anticipated in efficiency of care
and access to information out-of-hours. Implementation
involves large-scale sociotechnical change and should be
carefully planned, with consideration of training, evalua-
tion and impact on role. Small sample size and self-
select recruitment may have introduced sampling and
extreme response biases.
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A qualitative study to explore how a commercial ePre-
scribing system has been customised and what the bene-
fits and challenges were.
The National Health Service’s (NHS) Integrated Dig-
ital Care Fund and the Safer Wards, Safer Hospitals
Technology Fund has increased the implementation of
commercial electronic prescribing (ePrescribing) systems
in hospitals across the UK. Once implemented, these
systems are often customised according to the needs of
users to help improve their usability, and the safety and
quality of care delivered to patients.
The aim of this study, was to explore how a commer-
cial ePrescribing system had been customised in a large
UK teaching hospital, and what the benefits and chal-
lenges were.
After obtaining all relevant NHS ethical and organi-
sational approvals, a range of ward staff (e.g., doctors,
nurses, pharmacists) across four adult wards in a UK
teaching hospital and members of the hospital’s system
development team were recruited. One researcher con-
ducted 33 semi-structured interviews between Mar ‘15
and Aug ‘16, lasting between 17–70 min and performed
35 h of observations of users using the system. Users
were asked about their experiences of using the system
and any customised features. All interviews were tran-
scribed and checked for accuracy. These data were anal-
ysed using the Framework Approach.(1) Qualitative
data analysis software NVivo version 10 was used; a list
of themes were developed inductively, and explanations
for recurring patterns in these data were sought, refined
and presented.
Participants highlighted a number of key benefits and
challenges with customisation of the system: 1) some users
changed the layout of the medication list to improve the
visibility of an important information e.g., a medication’s
stop date. However, this came at a cost, as other informa-
tion (e.g., prescriber details) was now no longer visible;
one nurse was concerned she was “missing drugs and
doses” (P4; Nurse). 2) The organisation developed order
sentences and order sets to improve the safety and effi-
ciency of certain tasks. For example, prescribing regimes
that were error prone, which was “a really good way of
preventing that error from happening again” (P30; Phar-
macist). However, some users had difficulties remember-
ing the ‘key trigger words’ to identify them. 3) Users
reported insufficient use of Clinical Decision Support
(CDS) functionality and actively requested that more
alerts e.g., drug-drug interactions be switched on. 4) The
organisation also modified the system to enable patient’s
blood glucose levels and insulin to be reviewed and pre-
scribed electronically. However, if prescribing remotely,
decisions could be made in the absence of important
information not available on the system. 5) The organisa-
tion also developed a pharmacy task list, which helped
users work more efficiently, but lacked the sensitivity to
identify all ‘high-risk’ patients.
Users described several key benefits of customising
the system. However, issues with the design of the medi-
cation list and a lack of CDS prevented users from real-
ising the system’s full potential. This study took place at
one U.K. hospital Trust, and therefore may not be gen-
eralisable. Further research should focus on whether
similar problems have emerged with other systems and
organisations and how these could be addressed.
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Identifying indications for, and contraindications to
anticoagulant therapy are critical steps in ensuring safe
and appropriate use. Inaccurate risk assessment may put
patients at risk of adverse outcomes from over- or
under-use. Accessing electronic health data at the point
of care can promote accurate assessment of risk, and
encourage safe and effective anticoagulant use.
Our aim was to determine the feasibility of integrat-
ing a novel venous thromboembolism risk assessment
(VTE-RA) tool into a national Electronic Health
Record (EHR).
A collaborative, inter-disciplinary team was estab-
lished to undertake this proof of concept (PoC) within
an EHR virtual testing environment. An existing Micro-
soft Excel based VTE-RA tool was used as a template1.
Relevant clinical information which could be extracted
from the EHR environment and pre-populated into the
VTE-RA tool was identified, defined and agreed
(Table 1).
A prototype VTE-RA app was developed using
SMART on FHIR*, an emerging standards framework
that allows the development of interchangeable health-
care applications2. Integration was assessed by validat-
ing the accuracy of risk assessments carried out by the
app in a sample of virtual patients (n = 10). Ethical
approval was not deemed to be required.
Through interdisciplinary collaboration and use of
innovative technologies a prototype electronic VTE-RA
app was successfully developed and interfaced with the
EHR in a virtual testing environment. In all test cases
(n = 10), relevant clinical information was accurately
retrieved from the patient’s EHR and automatically
populated into the appropriate field in the VTE-RA
app, resulting in an accurate assessment of VTE risk.
The JavaScript code used by the app to calculate the
risk score was validated using 1000 sample cases.
We demonstrated that it is possible to interface a
VTE-RA app with an EHR. Seamless access to clinical
information in real time, at the point of care has the
potential to promote accurate VTE-RA, encourage
rational use of anticoagulant therapy and therefore
effectively prevent VTE.
At a broader level, scalable development and adop-
tion of SMART on FHIR apps across the spectrum of
Table 1 Sources of selected VTE risk factor information within the Cerner EHR environment
VTE Risk factor
Location of data point within EHR
Category Variable Example of data code
Age ≥ 35 years Observation > Social
History
Date of birth N/A
Parity ≥ 3 Observation > Social
History
Parity SNOMED Code: 440425000
Body Mass Index
(BMI)
Observation > Vital Signs Height N/A
Weight N/A
BMI N/A
Smoking status Observation > Social
History
Smoking status SNOMED Code: 449868002
Systemic infection Observation > Vital Signs White Cell Count LOINC Code - Leukocytes: 6690-2
Temperature LOINC Code –Temperature: 8331-1
Heart Rate LOINC Code – Heart Rate: 8890-6
Respiration Rate LOINC Code - Breaths: 9279-1
Medications > Medication
Order
Prescription of antimicrobial
agent
RxNorm Code - Ciprofloxacin: 2551
Caesarean delivery General Clinical >
Procedure
Procedure SNOMED Code - Emergency Caesarean Section:
274130007
General Clinical >
Procedure
Procedure SNOMED Code - Elective Caesarean Section:
177141003
Instrumental
delivery
General Clinical >
Procedure
Procedure SNOMED Code – Forceps delivery: 302383004
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health services has the potential to deliver smarter, safer,
and patient-centred care, ultimately contributing to
improved patient outcomes.
* SMART on FHIR: Substitutable Medical Apps,
Reusable Technology and Fast Healthcare Interoper-
ability Resource
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Pharmacists have worked in general practice for over
20 years. Their role has strengthened more recently with
the ‘Clinical Pharmacist in General Practice Pilot’,
launched in 20151, in response to declining GP numbers,
and the need for effective multidisciplinary team work-
ing. Research on the role of the pharmacist in general
practice has historically focused on the impact of phar-
macist-led interventions on patient outcomes. Emerging
research has explored pharmacist-led care in general
practice from the GP perspective2.
This study aimed to explore the experiences of phar-
macists in their new pilot clinical pharmacist role, and
gain an understanding of the GP the perspective.
A qualitative approach was undertaken, using face-to-
face, semi-structured interviews with a convenience sam-
ple of four GPs and eight pilot pharmacists from a multi-
partner GP surgery and satellite surgeries. The interviews
explored pharmacists as part of the primary care team,
their preparedness for the role and activities undertaken.
Interviews were audio-recorded, transcribed verbatim
and analysed in NVivo 10 using a constant comparison
approach. Ethical approval was obtained from the
School of Pharmacy Research Ethics Committee.
Three main themes were identified, including, role,
integration, training and support. Pharmacists described
their role as being largely undefined. While this allowed
for pharmacists and GPs to develop the role in line with
practice needs and pharmacist skills, it also created
uncertainty around expectations of the pharmacist, from
the perspective of the GPs, practice staff and pharma-
cists themselves.
Respondents held mixed views about pharmacist inte-
gration into the practice team. Although they felt
accepted and valued, some pharmacists did not feel fully
integrated because of the newness of a role that is unde-
fined, and time needed to bed into the team. For exam-
ple, pharmacists were unintentionally excluded from
practice meetings where they felt they could contribute
and learn about patient and practice matters. In con-
trast, one GP considered the pharmacist as having a def-
inite place in the team.
Practice-specific training was felt to be lacking and
both pharmacist and GP felt that an induction pro-
gramme would benefit pharmacists new to the practice,
particularly those from hospital and community phar-
macy that are also new to the setting. Clarification of
the pharmacist’s role was also considered to be an
important part of their induction to ensure they and the
practice team understood the pharmacist’s responsibili-
ties. Alongside training on the clinical system, it was
important for the pharmacists to understand the opera-
tional aspects of each practice – which often lacked poli-
cies and procedures to refer to – to help them prepare
for the role.
Although this is a small-scale study, which limits the
findings, it provides an insight into pharmacist and GP
perceptions of the pilot clinical pharmacist role. While
undefined roles, mismatched expectations of the phar-
macists’ responsibilities and in some cases lack of inte-
gration were identified; it must be recognised that this
pilot clinical pharmacist role is in its infancy and
requires time to develop. However, these findings may
help prepare future waves of pilot sites.
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Academic detailing or educational outreach is a form of
continuing medical education (CME) in which a trained
health professional, such as a doctor or pharmacist, vis-
its prescribers in their practice to provide unbiased evi-
dence-based information [1]. While academic detailing
has been adopted in Australia and the United States,
this strategy is not routinely used in Ireland.
The aim of this study was to assess the feasibility and
acceptability of a pharmacist-led academic detailing
intervention with a sample of practising GPs in a region
of southern Ireland.
Ethical approval was obtained for this study. Prior to
commencing GP recruitment, a meeting was arranged
with three GPs to discuss a topic for the intervention.
The intervention was delivered to GPs between June
and September 2016. A mixed methods feasibility study
was conducted, utilising quantitative data from patient
medical records in those ≥65 years with urinary inconti-
nence and qualitative data from focus groups with GPs
who participated in the intervention. The focus groups
were transcribed verbatim and analysed using thematic
analysis. The medical records for all patients aged
≥65 years who were attending a participating GP with a
diagnosis of urinary incontinence were retrieved and
analysed using a before-after approach. The measures of
prescribing assessed before and after the intervention
were: lower urinary tract symptoms-Fit fOR The Aged
(LUTS-FORTA) criteria, Drug Burden Index, and the
Anticholinergic Cognitive Burden scale.
The topic of urinary incontinence was selected by
GPs as they reported a desire to become more knowl-
edgeable about this condition. Twenty-three GPs partici-
pated in the academic detailing intervention and 14
attended focus groups. The mean number of partici-
pants per focus group was 3 (range 2–4). They described
the educational materials as being of high quality,
clearly presented, and easy to follow. Participants appre-
ciated the succinct nature of the information but would
have preferred a more easily retrievable format, such as
an online version rather than paper-based. The medical
records of 154 patients were analysed. The mean age
(SD) of patients was 75 (7.2) years. The proportion of
females was 72.1%. There was minimal or no change in
any of the prescribing measures used.
This study demonstrated that a pharmacist-led aca-
demic detailing intervention was acceptable to GPs in a
selection of different types of general practice in Ireland.
Overall, participants highly valued the evidence-based
approach of academic detailing. Nine of the GPs who
participated in the intervention weren’t available to
attend the focus group. All participating GPs were con-
tacted in advance about the focus groups; however,
some were on holidays on the scheduled date while
others who agreed to participate had to cancel at the
last minute due to time constraints during work or
emergency situations that arose with patients. There was
no control group used in the study, and as a result this
limited the comparison between the GPs who received
the intervention and those who didn’t. The findings
from this study will inform the planning and design of
larger studies, enhancing their likelihood of success.
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A comparison of electronic primary care
medication records as sources for
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Electronic summary care records (SCR) are routinely
used in hospitals to assist accurate medicines reconcilia-
tion[1]: two records used within an English Hospital
Trust are the national SCR and Egton Medical Infor-
mation System (EMIS). Despite both theoretically con-
taining identical GP data, some differences have been
noted locally.
The aim of this study was:
(1) To compare SCR and EMIS as sources for
medicines reconciliation.
(2) To determine the accuracy of medication records.
(3) To identify medication discrepancies.
(4) To assess the quality of allergy information.
This study was classified as an audit; ethical approval
was not required.
Patients who were prescribed a minimum of four
repeat medicines and had a medicines reconciliation
completed by a pharmacist using at least two sources[1]
were recruited. Patients who were unable to consent to
access to their electronic medication records were
excluded. The final pharmacist medicines reconciliations
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were used retrospectively as the ‘gold standard’ for com-
parison with SCR and EMIS records. Discrepancies
identified were classified in accordance with the UKMI
tool[2].
Hundred and five medicines reconciliations were
audited; 83 (79%) had used EMIS/SCR. SCR records
were available for 102(97%) patients and EMIS for 71
(68%) had they been needed.
Of the 102 SCR records 33(31%) matched the phar-
macists medicines reconciliation exactly; 228 discrepan-
cies were identified (2.2 per patient). For EMIS 24(23%)
records matched exactly; 133 discrepancies were noted
(1.9 per patient).
Discrepancies included 93 medicines not listed in
SCR/EMIS, 46 incorrect doses, 25 incorrectly discontin-
ued and 4 incorrect medicines. Approximately 70% of
discrepancies could have resulted in the omission of a
medicine; 28% were classified as severe (e.g. insulin),
32% moderate (e.g. antidepressants) and 40% minor
(e.g. laxatives) as per UKMI critical medicines tool[2].
SCR had 78% of patient reported allergies recorded
with reaction details for 35%; EMIS had 75% with
details for 9%.
The results show that neither SCR nor EMIS reliably
reflect all medication currently being taken by patients
and therefore should be used to inform the medicines
reconciliation process rather than being relied upon as
being comprehensive sources. A number of discrepancies
were identified in primary care records which, if unno-
ticed, could have caused unnecessary deterioration in
the patient’s condition. In line with WHO guidance a
minimum of two sources should be used for medicines
reconciliation whenever possible[2].
It is unclear why discrepancies occur but possible rea-
sons include medicines being accidentally discontinued
on the SCR/EMIS records by the GP, hospital only
medicines not being recorded on SCR/EMIS and hospi-
tal letters either not being received by the GP or not
acted upon.
Allergy information for many patients was incom-
plete which could lead to life-threatening events if
patients are inadvertently administered medication to
which they are allergic. In the future with increasing
polypharmacy it is imperative that there is one shared
comprehensive electronic medication record.
This study involved only two primary care systems,
the results may not be representative of other available
systems. The pharmacists’ medicines reconciliations were
used as the gold standard, however, on occasion errors
may have occurred due to the complexity of the process.
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Potentially inappropriate prescribing (PIP) is common
among middle-aged adults (45-64 years) in primary
care.(1) Little is known about adverse drug reactions
(ADRs) in middle-age, and how they relate to PIP. In
order to determine the risk posed by PIP and ADRs in
middle-age, data is needed on their prevalence, clinical
significance and association in this cohort specifically.
The aim of this study was to explore the relationship
between potentially inappropriate prescribing (PIP), as
identified by the PROMPT (PRescribing Optimally in
Middle-aged People’s Treatments) criteria, and adverse
drug reactions contributing to hospitalisation (cADRs)
in middle-aged patients.
A prospective observational study was undertaken.
The sampling frame was middle-aged patients presenting
to the Acute Medical Assessment Unit (AMAU) of the
study hospital. Patients using ≥3 medicines pre-admission
were included. Those who required an interpreter or pre-
sented with deliberate self-harm were excluded. The
PROMPT criteria were applied to each pre-admission
medication list to identify PIP. Patients were screened for
potential ADRs present at hospital presentation. Poten-
tial ADRs were assessed for strength of causality (Nar-
anjo algorithm) and those identified as possible, probable
or definite were categorised as ADRs. These were assessed
for preventability (Hallas criteria), severity (Hartwig
severity scale) and relationship to hospitalisation (senior
physician assessment). The association between PIP and
both ADR and cADR was investigated using the Pearson’
Chi-squared test. Multi-variate logistic regression analy-
ses were undertaken for PIP and ADR exposure [adjusted
for gender, age, Charlson Co-morbidity Index (CCMI)
score and polypharmacy]. A sample size of 100 patients
was required for multi-variate regression analysis, assum-
ing a PIP prevalence of 50% (dependent variable) with
five independent variables (2). Research ethics approval
was granted by the study hospital.
One hundred patients were recruited. Median age was
57 years [Inter-quartile range (IQR) 52-61], median
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CCMI score was 0 (IQR 0-1) and median number of pre-
admission medicines was 8 (IQR 5-10). Prevalence of PIP
was 48% of patients. 23 ADRs involving 38 drugs were
detected in 21% of patients. A total of 14% of patients
had a cADR, and 7% had a preventable cADR. Of the
23 ADRs, the majority (n = 14) were categorised as mod-
erate in severity. There was no association identified
between the presence of PIP and occurrence of cADRs
(x2=3.58, P = 0.06). Having PIP was associated with
occurrence of any ADR [adjusted odds ratio (aOR) 3.7,
95% CI 1.1-11.8] and with hospital admission from the
AMAU (aOR 3.8, 95% CI 1.2-12.4).
Presence of PIP was not associated with cADRs in
this study. However, it was associated with any ADR
occurrence and hospital admission. Additional research
is needed to further explore the relationship between
PIP and ADRs in middle-aged hospitalised populations,
and to identify the risk factors for same. Policymakers
should consider the burden which PIP and ADRs place
on limited healthcare resources in middle-age, and how
this may change as this population grows older. A
potential limitation of this study was its small sample
size, which may not have been sufficiently powered to
detect the association between PIP and cADRs.
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Two randomised controlled trials (RCTs)[1,2] conducted
in the same hospital in Southern Ireland have shown
that STOPP/START-based recommendations from a
physician or pharmacist can result in the reduction of
in-hospital ADRs for older adults (≥65 years). Both
physician and pharmacist applied STOPP/START crite-
ria to older patients’ medication lists and used their
clinical judgement to ensure only clinically relevant rec-
ommendations were made. The patient numbers (inter-
vention and control) were similar in the physician-led
RCT (n = 360 and n = 372) and the pharmacist-led
RCT (n = 361 and n = 376). The physician’s interven-
tion focused solely on STOPP/START recommenda-
tions, whilst the pharmacist’s intervention addressed
issues relating to STOPP/START, renal dose adjust-
ment, medication reconciliation, and other prescribing
criteria. Prescribers accepted 83.4% of the physician’s
recommendations and 54.8% of the pharmacist’s recom-
mendations respectively – this difference provided a
rationale for analysing the acceptance of STOPP and
START recommendations, as these were common to
both interventions.
The aim of this study was to compare the prescriber
acceptance rates of STOPP and START recommenda-
tions in these two RCTs, and provide a narrative sum-
mary of the cost and clinical outcomes.
This was a secondary analysis study of data from
two RCTs, which were stored locally in Microsoft
Access databases. The percentage (%) prescriber accep-
tance rates of recommendations made, based on
STOPP/START criteria version 1, were calculated. The
chi-square statistic was used to compare these prescriber
acceptance rates between the two intervention patient
groups. Ethical approval was granted for the RCTs to
be conducted and data analysis to be performed by our
research group. Consent was obtained from patients for
their data to be analysed.
Prescriber acceptance of the STOPP and START rec-
ommendations made by the physician were 81.2% and
87.4% respectively, which was significantly higher than
those made by the pharmacist (39.2% and 29.5%),
P < 0.0001. Prescriber acceptance of the pharmacist’s
recommendations regarding medication reconciliation
was significantly higher than the acceptance of STOPP/
START recommendations (77.1% versus 37.8%),
P < 0.0001. A greater absolute risk reduction in patients
with ADRs was shown with the physician’s intervention
compared to the pharmacist’s intervention (9.3% versus
6.8%).
The greater acceptance rate for the physician’s rec-
ommendations may be due to having a narrower inter-
vention focus, communicating the recommendations in
both oral and written form, and the physician having
an already recognised prescribing role within the hospi-
tal. Despite greater clinical effectiveness observed in
the physician-led RCT, economic evaluations of these
RCTs have shown the multifaceted pharmacist inter-
vention to be cost-effective, whereas the physician’s
intervention was not. A noted limitation of this study
is that the pharmacist’s intervention did not exclusively
focus on STOPP/START recommendations which may
weaken some of the conclusions drawn from direct
comparison of these RCTs. Future research should aim
to identify the barriers to prescriber acceptance of
pharmacist recommendations in the hospital setting,
with a focus on recommendations targeting medication
appropriateness. Further studies are also required to
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establish the best methods of communicating STOPP/
START-based recommendations in routine clinical
practice.
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Non-medical prescribers (NMPs) are making increasing
contributions to patient care; their prescribing decision-
making is subject to complex and contradictory influ-
ences[1].
The aim was to explore and describe influences on
NMPs’ prescribing decisions which they considered
noteworthy.
Seven pharmacist prescribers and five nurse pre-
scribers working in community pharmacy and primary
and secondary care in one Scottish Health Board area,
treating acute and long-term conditions, were partici-
pating in a wider programme of research into influ-
ences on their prescribing [1]. They were given digital
recorders and asked to identify and reflect on one or
two of their prescribing decisions which they consid-
ered noteworthy in some way. No other guidance was
given on the reflection. Recorders were returned to the
research team and reflections transcribed verbatim.
Individual semi-structured interview schedules were pre-
pared based on each reflection, the Theoretical
Domains Framework (TDF)[2] and findings from earlier
research[1]. Participants were interviewed at their work-
places by a trained researcher and the interviews
recorded, transcribed verbatim and analysed themati-
cally by two independent researchers. Earlier findings
including the domains of the TDF were used as the
initial coding framework. Approval was received from
a university ethics committee and NHS Research and
Development department; NHS Ethic’s approval was
not required.
Participants recorded 24 reflections on noteworthy
prescribing decisions; subsequent interviews lasted
between 5 and 33 minutes Participants described most
of their decisions as involving vulnerable patients, multi-
ple morbidities, lack of information and/or the need for
creative thinking to optimise patient outcomes. Deci-
sions ranged from treatments of long-term conditions to
an acute life-threatening medicine-related event and
often involved multidisciplinary working. Several con-
cerned antibiotic prescribing. Knowledge of the condi-
tion, the patient and of medicines were important
influences. Participants described using a range of skills,
particularly communication skills but also physical
assessment and calculation skills, and balancing com-
plex, conflicting responsibilities. Participants’ roles as
nurses, pharmacists and prescribers were also influential
as were previous experiences. Participants valued the
opportunity as prescribers for more direct patient care
but reported being acutely aware of attendant additional
responsibilities. Beliefs about the consequences of their
prescribing decisions for patients and for others were
influential; participants put patients at the heart of their
prescribing decision-making. They described taking a
careful, rigorous and step-wise approach although
heuristics played a part in familiar situations and previ-
ous experience was important. Most reflections evi-
denced participants feeling very capable and competent
in prescribing but they were aware of their limitations
and knew when to seek help from other members of the
multidisciplinary team, in primary care most often from
GPs. The social influence of patients and occasionally
patients’ families was sometimes important: demands for
antimicrobials were hard to resist. The medical hierar-
chy was problematic for one participant.
NMPs’ noteworthy prescribing decisions were subject
to multiple influences; complexity was a feature and an
influence in many. While findings in this small-scale
study may not be transferrable they endorse NMPs’ pre-
scribing practice but suggest that additional education
and training may be needed to support evidence-based
antimicrobial prescribing.
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Preparation for future non-medical
prescribing roles: survey analysis of
pharmacy trainee’s perceptions in the
prescribing safety assessment pilot
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The role of non-medical prescribing is becoming increas-
ingly important and we must adequately prepare phar-
macy trainees to undertake this role; this has been
explored across multiple sites using the Prescribing Safety
Assessment.
The aim was to assess whether pharmacy trainees
perceived current MPharm and Pre-registration training
curriculums as adequate preparation for the Prescribing
Safety Assessment (PSA) and to examine what scope of
prescription writing practice students have had during
their training.
Final year MPharm and preregistration pharmacist
trainees undertook an abridged Prescribing Safety Assess-
ment1 from March to May 2017. This aimed to assess the
equivalent level of knowledge and skill as the PSA exam
undertaken by final year medical students, differing in
assessment length (reduced number of questions) with
some modified content. Six regional pre-registration pro-
viders (London and South East, East of England, Thames
Valley, East Midlands, Yorkshire and Humber, and
North East) and seven schools of pharmacy (Bradford,
Durham, Keele, Manchester, Nottingham, Portsmouth
and Sunderland) recruited final year pharmacy under-
graduate students and pre-registration pharmacy trainees
with both hospital and community pharmacy employers
to take part. Consent was obtained from candidates and
full ethical approval was gained from the University of
Sunderland. On completion of the exam, candidates were
asked to complete a standard feedback form provided by
the PSA team. Thematic analysis was applied to free-text
comments and quantitative data collated.
Feedback was obtained from 1059 candidates, (re-
sponse rate 94%). 42% of candidates (n = 445) agreed
or strongly agreed that their pharmacy course had pre-
pared them to undertake the PSA whilst 27% (n = 289)
felt it had not; the remaining having a neutral opinion.
78% (n = 822) of candidates reported having written
less than five prescriptions throughout their pharmacy
training. Thematic analysis of free-text comments
obtained in response to the questions ‘were any particu-
lar items [on the assessment] unclear or unreasonably
difficult?’ and ‘do you have any comments regarding the
PSA or prescribing education?’ revealed three emerging
themes: (i) Relevance of the assessment to pharmacy
trainees (ii) Content and breadth of pharmacy training
(iii) Clinical experience and exposure.
Stakeholders involved in the planning and delivery of
pharmacy education may find the results from the can-
didate feedback from the PSA pharmacy pilot enlighten-
ing and could potentially use this insight to inform
future curriculum content and in practice training. The
majority of pharmacy trainees claimed to have only had
the opportunity to write less than five prescriptions in
their 4 or 5 years of training at the point the assessment
was undertaken. The marked differences in responses
may be explained by trainees interpreting “writing on a
prescription chart” variably ranging from simulation
through to direct observation. Furthermore, there
appeared to be a lack of understanding of the relevance
of prescribing for pharmacy trainees, both from the per-
spective of them directing others to prescribe (e.g. medi-
cal prescribers) and as potential future non-medical
prescribers themselves. There is scope to improve the
preparation and awareness of pharmacy students for
future prescribing roles.
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An exploration of social media and
eprofessionalism in pharmacy practice
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To date, the literature on the use of social media
(SoMe) within pharmacy has a distinct lack of focus on
use by registered pharmacists, with the main body of
evidence relating to pharmacy students.1,2 Literature
suggests a need for professional guidance to support
individuals in their use of social media, with references
being made to eprofessionalism and fitness to practise.
A systematic review (SR) of professional body and regu-
latory organisation guidance for healthcare professionals
carried out by the research team showed a lack of con-
sistency of approach to professional guidance and a
focus on what not to do rather than shedding light on
appropriate online behaviours. In addition, caution is
advised with regards to social media use and, in particu-
lar, with regard to blurred boundaries between personal
and professional personas.
This study sought to explore how eprofessionalism
and ‘appropriate’ online behaviour is defined and char-
acterised and to explore when online behaviour ‘crosses
the line’ and becomes ‘inappropriate’.
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Four activity based workshops were conducted at
two pharmacy conferences (BPSA, HSRPP) and two
Royal Pharmaceutical Society workplace venues. Activi-
ties were developed around defining eprofessionalism,
gauging personal/professional use of social media,
exploring (in) appropriate behaviours and responding to
case scenarios. Each was informed by existing literature,
a previous SR and pilot study. Themes were inducted
from analysing the textual content of the focus groups
and responses to other activities collated and synthe-
sised. The research was approved by the School of Phar-
macy and Life Sciences Ethical review panel.
A total of 101 participants representing pharmacy
practice, pharmacy students, academics and administra-
tors consented and took part. No single definition of
eprofessionalism emerged, but common themes relating
to appropriate online behaviour (not just social media)
emerged such as respecting others, keeping all communi-
cation ‘professional’ and maintaining a professional per-
sona similar to that in an off-line environment. A wide
range of uses of social media were noted for both per-
sonal and professional roles. Inappropriate behaviours
were identified with a focus on activities deemed to be
not appropriate online such as swearing, bullying/trol-
ling and sharing of inappropriate or non-factual infor-
mation. Appropriate behaviours focussed on activities
such as sharing photographs, evidence-based informa-
tion and providing encouragement/being polite. How-
ever, there was little consensus on the appropriateness
of the behaviours described in the cases with partici-
pants viewing (in) appropriate behaviours and fitness to
practice issues differently. This will be further explored
in the next phase of research.
The lack of shared definition of eprofessionalism and
appropriateness of online behaviours highlights the need
for a clearer understanding amongst healthcare profes-
sionals and the wider population. With no consensus on
how to engage positively with SoMe or where the line
between (in) appropriate lies further research is indi-
cated. A further phase of research is underway using a
nominal group technique aiming to gain consensus on
appropriate behaviours and inform recommendations on
the provision of guidance.
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A quantitative investigation of MPharm
students’ study habits and where they
turn for academic support
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Students’ transition to university is often a daunting
experience; 1 increased student numbers have affected
the pedagogy of science in higher education and the pro-
vision of personalised contact between students and aca-
demic tutors in becoming increasingly problematic.
The aim of this study was to investigate MPharm
students’ study habits and determine where they turned
for academic support with their studies.
A questionnaire with a mix of eight open and ten
closed questions, was developed to gather data about
students’ perceptions of their academic workload, opin-
ions of university study support services and where they
turned for academic study support. Following piloting,
Stages 2, 3 and 4 MPharm students, potentially 365 stu-
dents, were recruited opportunistically by distributing
questionnaires at the end of a lecture, and invited to
participate by submitting their completed questionnaires
as they left the lecture theatre. Stage 1 were excluded as
it was deemed too early in the course to gather reliable
data. Data was input into Microsoft Excel for analysis;
descriptive statistics were used to analyse the closed
questions and responses to open questions were anal-
ysed using content analysis. This study underwent insti-
tutional ethics approval.
A total of 234 questionnaires were returned. Stu-
dents’ perceptions of workload varied according to gen-
der and ethnicity, more non-white students (Chi-square
= 17.2132, P < 0.001) and female students (Chi-square =
6.5498, P = 0.0149) reported heavier workloads. Stu-
dents stated they preferred unofficial study support net-
works such as their peers and higher year students as
opposed to contacting lecturers or using official univer-
sity support services. Only 39% (n = 224) of respon-
dents reported accessing university study support
services and yet a high proportion of non-users 75%
(n = 146) reported their workload as either heavy or too
much. More students reported they had failed more
exams in Stage 1 of their MPharm degree than in any
other academic year of their course (Chi-square =
123.9447, P < 0.001). Meanwhile exam performance was
affected by nerves, last minute revision and focusing
their revision on other subjects. Students’ perceptions of
the helpfulness and relevance of university support pro-
vision influenced their decision upon whether to seek
such support. A large majority (88% n = 234) thought
higher year student mentors could support new students
with their studies and thought mentors would be more
approachable than lecturers.
Students in this study preferred to seek academic sup-
port from peers or higher year students as opposed to
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using official university study support services. Their
decisions to access official academic support services
were influenced by their perceptions of the relevance
and helpfulness of the support being provided. The
introduction of a peer mentor programme could help
new students to manage their workload and prepare for
assessments. A limitation is that this study was con-
ducted in a single school of pharmacy, which may limit
generalisability to all student pharmacists in different
settings and different degree programmes.
References
1. Fitgerald P. Easing the transition to university: suc-
cessful student induction 30th April 2014. Available
from: https://www.heacademy.ac.uk/resources/detail/
resources/detail/stem-conference- 2014/Post_event_re-
sources/Bioscience/Easing_the [Accessed 05 October
2017].
Urgent Care
Medicines use in the emergency
department: exploring professionals’
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Medicines are a common emergency department (ED)
medical intervention. Due to their expertise, there is an
increased focus on the potential role for pharmacists in
the ED.[1] The use of medicines in this setting (prescrib-
ing, dispensing, administration and monitoring) has his-
torically been the concern of doctors and nurses.[2] With
ED pharmacist roles seemingly becoming more com-
monplace, it was important to better understand the use
of medicines in the ED and therefore how pharmacists
could best support their use.
To investigate ED professionals’ perceptions of
medicines use in the ED.
Semi-structured interviews with six doctors and six
nurses took place in the two EDs of Lancashire Teach-
ing Hospitals (LTH) after obtaining ethical approval.
The topic guide was structured according to the four-
stage medicines use process. Further topics for discus-
sion were identified from a review of relevant literature
and an observation visit to the Royal Preston Hospital.
Interviews were recorded, transcribed verbatim and
analysed thematically.
There were clear differences and similarities between
doctors’ and nurses’ perceptions of the four major areas
of the medicines use process. Most of their perceptions
were linked to patients, staff or resources.
A majority of participants think prescribing in the ED
is “simple” and “straight-forward” and most of them said
they use the British National Formulary to support pre-
scribing. However, one doctor did express their frustra-
tions with the lack of prescribing guidelines and support
immediately available in the ED for elderly or obese
patients. Participants explained why appointing an ED
pharmacist would be “beneficial” to medicines use and
described pharmacists as “helpful” and “fantastic”.
At LTH, the pharmacy’s dispensing services are not
available 24/7. Participants recalled times when they
would discharge patients from the ED without their dis-
charge medicines and patients would come back the
“following day” to get them. Many participants said
they would “run out” of medicines either when the
pharmacy is closed, over the weekend or during bank
holidays.
The overall consensus was that the documentation of
medicines use is done frequently. Whenever medicines
are administered another person would document it and
sign for it. One participant believes documentation in
the ED is “better than on certain wards”. However, par-
ticipants did mention that there are sometimes “delays”
in the administration of medicines during hectic times.
ED professionals sometimes monitor patients’
response to medication. The nature of monitoring
depends on the type of medication given and the
patient’s condition. Monitoring is done “regularly” but
when the ED is “busy”, a few doctors admitted that
monitoring patients is “difficult”. One nurse explained
how poor communication from doctors led to patients
being unmonitored.
This study has provided a foundation for further
research of medicines use in the ED and highlighted
areas requiring pharmacy input. Data saturation was
not reached so more ED professionals could have been
interviewed. However, using semi-structured interviews
helped reveal new and valuable information that can be
used to support development of ED pharmacist roles
which are of value to both patients and professionals.
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A pilot study of pharmacists working in
an advanced role in the urgent care
centre (UCC), emergency department
(ED): a quantitative study
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The 5-year forward view highlights the significant work-
force shortage in the ED. Pharmacists can be upskilled
to bridge this gap and meet the evolving healthcare
demands1. This study aims to determine if pharmacist
advanced clinical practitioner trainees (PACPt) equipped
with advanced skills such as clinical assessment and
diagnostic interpretation are able to manage patients.
To determine the extent of how pharmacists with
advanced skills can manage patients in the UCC.
To determine the proportion of patients presenting to
the UCC that were seen by pharmacists. To determine
levels of investigation, establish diagnosis, adequacy of
current skills to perform tasks and re-attendance rates
in patients seen.
A retrospective, quantitative study of patients attend-
ing the primary care area of the UCC at Queen’s Hospi-
tal and managed by PACPt. Data on the number of
patients seen over a 3 month period was collated follow-
ing an initial pilot. Diagnosis by clinical grouping, inves-
tigations and re-attendance figures were sought.
Assessments were made on whether PACPt were
equipped to manage patients in the UCC or if addi-
tional skills were required. Ethics approval was not
required, as the research department in the hospital
deemed the study a service development initiative.
A total of 1252 patients presented to the UCC during
the study period. The PACPt managed 32.7% (n = 410)
patients under the supervision of the UCC general prac-
titioner (GP) lead. Of these, 72.4% were adult and
27.6% were paediatric patients. The PACPt were able to
manage 82% of these patients with their current skillset
and required additional skills in 18% of cases. Investiga-
tions were requested for 24.4% of these patients prior to
making a formal diagnosis. Musculoskeletal disorders
were the most common diagnosis. The re-attendance
rate was 9% from the 410 patients seen by the three
PACPt. From the 9% who re-attended, 24.3% were due
to a similar presenting complaint and were managed
identically.
Pharmacists with advanced skills were able to man-
age 32.7% of the workload. This is comparable to
results from a similar study2. This sets a baseline for
future work and demonstrates the ability of PACPt to
manage patients presenting with minor injuries, long
term conditions and acute emergencies.
A limitation of the study was level of training, as
trainees were approaching the halfway point of the uni-
versity programme and had not completed their
training. Some investigations were being ordered unnec-
essarily at triage prior to consultation. An element of
subjectivity was introduced as additional skills required
to manage patients were determined by the trainees. Re-
attendance figures may not be a true reflection of
PACPt input, as all patients were reviewed by the GP.
A re-audit towards the end of training focusing on
the accuracy of diagnosis and management plan, patient
satisfaction and breakdown of specialist skills used is
recommended. This would shed light on the ability of
pharmacists with advanced skills to work autonomously
and safely.
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Prescribing II
Retrospective longitudinal study of
patients and prescriber characteristics
associated with new DOAC prescriptions
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Direct oral anticoagulants (DOACs) uptake for stroke
prevention in atrial fibrillation has been slow.[1] This
study aimed to profile the prescribing of DOACs over
3 years to identify factors associated with DOAC pre-
scribing in a Clinical Commissioning Group (CCG)
without restrictions to DOACs use. The objectives were
to identify:
(1) Characteristics of patients prescribed oral anticoagu-
lant (OAC) in a sample of general practices;
(2) Who initiated the prescribing of OAC?
(3) Recorded reasons for prescribing a DOAC rather
than warfarin;
This retrospective longitudinal study of OAC pre-
scribing in adults used anonymous data submitted from
nine general practices in Bradford, England. Ethical
approval was granted by the University of Bradford.
Practice pharmacists extracted anonymised data from
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the TPP-SystemOne clinical software by running pre-
defined searches to identify new OAC prescriptions.
Data was descriptively analysed with Excel and SPSS.
The results are summarised in Table 1. The propor-
tion of DOAC prescribing significantly increased over
time (x2(2) =63.538, P < 0.01). There were no statisti-
cally significant differences between age, gender and type
of OAC and who initiated the OAC. However, the
majority of DOACs were initiated in the community
showing general practitioners’ increasing confidence in
DOAC prescribing. Documentation of reasons for
choosing a particular OAC was poor and almost non-
existent for warfarin. Patient choice was increasingly
stated as a reason to prescribe a DOAC indicating
greater patient involvement in a shared decision-making.
One third of patients were switched from aspirin to
an OAC over time and they were statistically more
likely to be initiated on warfarin than a DOAC (x2(1)
=13.923, P < 0.01). This observation was significant only
in the community initiated prescribing (x2(1) =12.693,
P < 0.01). The effect decreased over time. Changing
between OAC over the study period was more common
for patients prescribed warfarin (29%) than a DOAC
(4%). The main reason for switching from warfarin was
inadequate control of time in the therapeutic range.
Results of this study will be used to inform a larger
study on the organisational barriers to DOACs prescrib-
ing. The main limitation was inclusion of surgeries with
practice pharmacists only. This work was made possible
with unrestricted educational grant from Bayer Pharma-
ceuticals.
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perceptions of their medication
communication with prescribers
M. Lloyda, S. D. Watmoughb, S. V. O’Brienc,
N. Furlonga and K. Hardya
aSt. Helens and Knowsley Teaching Hospitals NHS Trust, UK bEdge Hill
University, UK and cSt. Helens Clinical Commissioning Group, UK
Michael.lloyd@sthk.nhs.uk
Prescribing errors are common and problematic in hos-
pital settings in the UK. [1] Pharmacists have been
described as integral in the interception of prescribing
errors, with effective medication communication
between pharmacists and prescribers important to
resolve and optimize prescribing outcomes. However,
poor communication between healthcare professionals,
including pharmacists and prescribers, is considered a
leading cause of prescribing error. [1]
Pharmacists’ medication communication with pre-
scribers has been reported as limited in the literature,
whilst they have been described as working indepen-
dently to doctors. Additionally, pharmacists have
Table 1 Summary of the baseline characteristic of patients newly prescribed OAC in Bradford, from 1/4/2012 to 31/
3/2015. *Other: can’t attend warfarin clinic, needle-stick phobia, or drug interaction with warfarin.
1/4/2012-31/3/2013 (n=140) 1/4/2013-31/3/2014 (n=138) 1/4/2014-31/3/2015 (n=146)
Warfarin
(n=120)
DOACs
(n=20)
Warfarin
(n=84)
DOACs
(n=54)
Warfarin
(n=58)
DOACs
(n=88)
Age (years), mean (SD) 76 (11) 77 (10) 76 (10) 76 (10) 76 (10) 76 (10)
<66 (number of cases) 18 2 12 7 15 9
66-75 (number of cases) 27 6 26 15 18 20
>75 (number of cases) 75 12 46 32 25 59
Sex, male 56% 65% 56% 59% 45% 45%
OAC split 86% 14% 61% 39% 40% 60%
Initiator
Community 77% 80% 66% 74% 66% 83%
Hospital 21% 15% 32% 26% 34% 17%
Not stated 2% 5% 2% 0% 0% 0%
Started as 1st line 85% 9% 60% 23% 38% 40%
Reason for choosing as 1st line:
Patient choice 1% 18% 1% 44% 2% 46%
Not stated 99% 73% 99% 56% 98% 45%
Other* N/A 9% N/A 0% N/A 9%
Switching (number of cases)
Aspirin to warfarin or
DOAC
59 9 33 16 17 17
Warfarin to DOAC N/A 8 N/A 27 N/A 40
DOAC to warfarin 0 N/A 5 N/A 2 N/A
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previously described communication apprehensions with
doctors, [2] with these apprehensions creating barriers to
effective medication communication with prescribers.
The aim of this study was to explore the perceptions
and views of hospital pharmacists on their medication
communication with prescribers.
The study was undertaken in a large acute teaching
hospital in the North West of England. All (n = 37) hos-
pital pharmacists were eligible to participate. An invita-
tion to participate was communicated verbally at a
departmental meeting and via e-mail.
In-depth, semi-structured, face-to-face interviews
were used to explore pharmacists’ perceptions of medi-
cation communication with prescribers. The topic guide
was informed by the literature and previous research to
explore how pharmacists communicate with prescribers
about medications, and how they have learnt inter-pro-
fessional medication communication skills.
All interviews were digitally recorded and transcribed
by the researcher. Interviews lasted an average of
32 minutes (21–48 minutes) and data saturation was
achieved by the fifteenth interview. A thematic analysis
was performed manually by the researchers with initial
codes discussed and consensus achieved through regular
meetings.
Relevant hospital and University of Liverpool ethics
committees’ approval was obtained before commencing
this study.
Twenty-nine pharmacists volunteered to participate
and were interviewed. A range of pharmacist grades
(Agenda for change band 6–8b) were recruited.
Three key themes emerged from the data: Communi-
cation skills training, medication communication with
prescribers, and pharmacist as a communicator. Pharma-
cists reported that training in medication communication
with prescribers was limited with these skills developed
mainly through postgraduate experience and reflection.
Medication communication was inconsistent between
pharmacists with a range of written and verbal communi-
cation reported. Barriers to medication communication
with prescribers included pharmacy service provision,
workload, perceived urgency of the medication issue, pre-
scriber rapport and communication anxiety. Expectations
of junior pharmacists were considered unrealistic and
contributed to unnecessary medication communication
apprehensions with prescribers. The limited medication
communication reported appeared to contribute to a
sense that hospital pharmacists worked in parallel to the
clinical team. The need for greater contextualized training
in inter-professional communication was reported to pre-
pare pharmacists for the challenges of hospital practice.
This is a qualitative case study with limited generaliz-
ability, although a wide range of pharmacists were inter-
viewed typical of a UK hospital pharmacy department.
This is the first known UK study exploring pharmacist-
prescriber medication communication in a hospital set-
ting in-depth, and has raised awareness of barriers to
effective medication communication, and the need for
enhanced communication-skills training to support the
hospital pharmacist workforce.
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Deprescribing is the process of identifying and discon-
tinuing inappropriate medicines and has been associated
with positive patient outcomes in certain circumstances1.
Deprescribing a medication may be in response to pre-
sent observed harm (reactive) or future gains being unli-
kely/preventing future harm (proactive). A hospital
admission, where routine medicines reconciliation and
physiological monitoring are undertaken may present an
opportunity to develop a deprescribing intervention.
Understanding current deprescribing practice in hospital
is a key precursor to intervention development.
The aim of this study was to describe the extent and
nature of hospital deprescribing practice.
After confirmation as a service evaluation from the
University of East Anglia Research Ethics Committee, a
retrospective analysis of Electronic Prescribing and
Medicines Administration (EPMA) data pertaining to
pre-admission medicines at a large UK teaching hospital
was undertaken in February 2017. Patient demograph-
ics, medicine details and prescriber’s rationale for medi-
cation discontinuation (selected from a pre-defined list
of reasons on EPMA) were analysed. Medicine discon-
tinuations associated with reasons not consistent with
deprescribing, such as “prescribed in error” were
excluded. A stratified sample of 200 discontinued
medicines were further analysed by reviewing medical
records to determine the prescriber’s rationale. This was
used to categorise the deprescribing activity into proac-
tive and reactive as previously defined. These data were
extrapolated in order to estimate the total proportion of
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pre-admission medicines deprescribed and the propor-
tion which were reactive and proactive. Descriptive
statistics were used to report the findings.
From 24552 pre-admission medicines prescribed for
2309 patients, 977 discontinuations were recorded of
which 682 (69.8%) were consistent with deprescribing
according to the selected EPMA reason. These discontin-
uations were distributed across 415 patients with a med-
ian (IQR) age of 79.0 (66.0, 86.0) years. Of the 200
sampled discontinuations, 137 (68.5%) were not consis-
tent with proactive or reactive deprescribing as defined in
the introduction and 15 (7.5%) were undeterminable from
the medical records. The remaining 48 (24.0%) confirmed
deprescribing activities were categorised into 10 (20.8%)
proactive and 38 (79.2%) reactive. Extrapolation of this
sample data to the 682 discontinuations yielded 22.7%
(95% confidence interval 19.5%-25.9%) consistent with
deprescribing which was 0.63% (95% confidence interval
0.32%–0.94%) of all pre-admission medicines.
This evaluation demonstrates very limited deprescrib-
ing activity is taking place in this one hospital. The pro-
portion of pre-admission medicines prescribed in
hospital which are inappropriate is estimated at almost
30%2, suggesting that opportunities to deprescribe are
being missed. There may therefore be significant scope
for increasing deprescribing activity in hospital and a
role for hospital pharmacists to either facilitate or
implement this, but the extent to which deprescribing is
acceptable and feasible is as yet unknown. Dominance
of reactive behaviour suggests prescribers require evi-
dence of present harm to prompt deprescribing.
The large proportion of the sampled medication dis-
continuations that had been assigned an incorrect
EPMA reason by the prescriber limits the utility of the
electronic prescribing data. However, this limitation of
data quality was overcome by extrapolation of data
from the manual review of medical records in order to
estimate the prevalence of deprescribing activity.
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Accessing Palliative Medicines (PMs) towards the end of
life is critical to achieving effective symptom control,
however there is little published research on community
pharmacists’ (CPs) role in providing access to PMs
within the context of community pharmacy in England.
The aim of this study was to determine factors
impacting on the CP’s role in supporting access to PMs.
The objectives in this study were to:
(1) Investigate factors facilitating or hindering access to
PMs in community pharmacies.
(2) Examine views of CPs and community healthcare
professionals on the CP’s role in accessing PMs.
A sequential mixed methods study collecting anon-
ymised prescription data from a purposive sample of
five community pharmacies in Sheffield followed by
in-depth individual semi-structured interviews with 16
community healthcare professionals was undertaken.
Two of the five pharmacies provide access to PMs under
a Locally Commissioned Service (LCS). Here we focus
on the qualitative study. Participants consented to a 1:1
interview exploring factors facilitating timely access and
the CP’s role. Interviews were transcribed verbatim and
analysed using the Framework method. (1) Analysis fol-
lowed an inductive and iterative thematic process. Ethi-
cal approval was obtained from the University of
Bradford.
Interviews were completed with CPs (5), GPs (3),
community nurses (5), palliative care team (2), and
intermediate care team (1). Three themes emerged (i)
environment and resources, (ii) communication and col-
laboration, (iii) skills and knowledge. (i) CPs reported
providing a primarily reactive role when faced with a
prescription for PMs with little advanced planning. They
described practical issues including: controlled drug cab-
inet size; national stock shortages; ordering processes;
and prescriptions for items not on the local formulary.
Having stock of PMs in the pharmacy was the main
facilitator supporting timely access with nurses wanting
more pharmacies to keep some basic PMs in stock. (ii)
Community healthcare professionals indicated they may
contact the pharmacy to check availability, but
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palliative care needs were not discussed in advance with
CPs due to concerns about sharing confidential informa-
tion. There was poor understanding of the LCS, the
CP’s professional role, and pharmacy services of poten-
tial benefit to palliative care patients. Examples where
CPs working with GPs or nurses to support access to
PMs relied on effective communication and face to face
relationships. (iii) Community healthcare professionals
expressed concern that CPs were not familiar with pre-
emptive prescribing or understand the urgency in which
PMs were needed.
Despite the national direction to increase the CPs
involvement in palliative care(2) they lack clinical infor-
mation and integration into primary care teams. It is
suggested that better integration and sharing of informa-
tion between primary care team members will support
timely access to treatments. Findings may be limited due
to variations in commissioning and geographical loca-
tion. Further research on CP integration using modern
technologies is warranted.
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English NHS policy emphasises improving healthcare
quality across three dimensions – patient experience,
clinical effectiveness and patient safety – with a system-
atic review suggesting that all three are consistently posi-
tively associated.1 In community pharmacy, medicines
use reviews (MURs) which have faced recent scrutiny
with the suggestion that some organisations may priori-
tise the quantity of service provision over quality.2
Part of an NIHR-funded study of clinical productiv-
ity in English community pharmacies, this paper aims to
determine the organisational factors associated with
patient experience, clinical effectiveness and patient
safety.
Following National Research Ethics Service approval
(13/WM/0137), two surveys were undertaken: one of
community pharmacies in nine diverse primary care
administrative areas of England capturing organisational
and patient safety characteristics (PSCQ; 24 items e.g.
“All staff are constantly assessing risks and looking for
improvements”), and one of patients in receipt of NHS
services (dispensing/MURs) in 39 participating pharma-
cies capturing data on satisfaction with pharmacy visits
(15 items e.g. “My concerns were taken seriously”) and
information about medicines (SIMS; 16 items e.g. “Have
you received enough information about how to take
your medicine?”), and medication adherence (MARS; 5
items e.g. “I alter the dose”). Regression analysis
explored associations between these outcomes and ser-
vice volume, patient-, pharmacy- and areal-specific
demographic, socio-economic and health-needs vari-
ables, obtained from the NHS Business Services Author-
ity, patient and pharmacy surveys, and national
datasets. Data were linked by unique NHS organisa-
tional identifier and postcode.
Pharmacy survey (valid response rate 277/800
(34.6%)): pharmacies had a significantly less favourable
safety climate where the organisational culture was more
closely aligned to quantity, the medicine and technical
work than to quality, the patient and professional work,
where the pharmacist worked longer hours, and who
employed an accuracy checker. Safety climate (PSCQ)
was significantly associated with pharmacy type (large
multiples/supermarkets had more favourable organisa-
tional learning scores but less favourable working condi-
tions scores) but not service volume.
Patient survey (valid response rate 971/2087
(46.5%)): greater satisfaction with pharmacy visit was
significantly associated with the employment of a phar-
macy technician, having more reasons for choosing to
visit a particular pharmacy, and continuity of advice-
giver. Older patients were significantly more satisfied
with the information they received about medicines and
more likely to be self-reported adherers. Higher SIMS
scores were also associated with continuity of advice-
giver and weaker belief in medicines overuse. Regular
use of locums was associated with poorer self-reported
medicines adherence as was stronger belief in medicines
overuse. Neither satisfaction, SIMS nor MARS scores
were associated with pharmacy type or service volume.
These findings, although limited by a low response
rate, non-participation of five of the nine largest phar-
macy chains, and the limited availability of validated
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outcome measures for community pharmacy, have iden-
tified a number of organisational and patient factors
associated with NHS service quality in community phar-
macy. In particular, they suggest that pharmacies should
focus on staffing and skill-mix to improve quality.
Whilst the importance of quality is clearly recognised by
policy makers, further research is needed to identify and
validate quality indicators in community pharmacy.
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Promotion of self-care has led to an increase in patients
seeking advice at pharmacies. To facilitate staff estab-
lishing a diagnosis, mnemonic standardised protocols
have been developed and promoted. These tend to be
easily remembered and used, however, their usefulness
has not been proven. Clinical reasoning, a combination
of evidence-based knowledge, professional experience
and practice, is a more complex process, however, it can
be more accurate and improve diagnostic ability. It has
not been established how mnemonic and clinical reason-
ing criteria are used in literature assessing pharmacy
consultations which require a diagnostic assessment.
The primary aim of this review was to summarise the
criteria authors use to assess pharmacy staff’s diagnostic
performance and to what degree they conform with a
clinical reasoning and a mnemonic framework. A sec-
ondary aim of the review was to characterise staff per-
formance in the studies, based on the author’s
comments of their results.
Three online databases were searched to identify suit-
able papers for review. After an initial scoping, a search
algorithm was decided and two rounds of searches were
carried out. Two of the authors performed the screening
while the third author acted as an arbitrator. Only peer-
reviewed studies that used simulated patients or vign-
ettes to assess and describe staff performance were
included. All study designs were acceptable for inclu-
sion. Data were extracted about how each study’s crite-
ria conformed to clinical reasoning and mnemonic
frameworks. For this, each framework was broken
down into 4 characteristics based on researchers’ assess-
ment of staff’s decision-making process. Study texts
were qualitatively analysed and coded for passages that
corresponded to each characteristic. A value of one was
assigned for each characteristic exhibited, meaning each
study could score between 0 and 4. No ethical approval
was needed for this review.
Sixty-eight studies from 29 countries, published
between 1989 and 2017, were included in the review.
Based on our scoring system, the studies had an average
score of 2.71/4 for elements of mnemonic criteria in
their frameworks and an average score of 0.96/4 for
clinical reasoning elements. Fifty-one of the studies
reported negative comments in their assessment of staff
performance, 9 used positive comments and 8 used a
mix of positive and negative comments.
On average, studies utilise more mnemonic than clini-
cal reasoning elements when assessing community phar-
macies’ staff diagnostic performance. Performance, as
reported by study authors, was generally poor.
Researchers should include more clinical reasoning crite-
ria in their assessment frameworks, which will allow for
the relevance of the gathered information to be assessed,
as well as staff’s evidence-based knowledge and experi-
ence and their ability to interpret and synthesise infor-
mation. Furthermore, community pharmacy staff should
receive appropriate training for the quality of the con-
sultations to improve. Strengths of this review include
the low risk of interviewer and recall bias, however,
there’s bias risk due to the exclusion of grey literature
and studies not written in English.
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People with dementia (PWD) face unique challenges in
their ability to successfully manage their medicines,
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requiring the development of pragmatic interventions to
improve patient outcomes. Intervention development
should be both theory- and evidence-based, and include
those who will be involved in intervention delivery, i.e.
healthcare professionals (HCPs). The 14-domain Theo-
retical Domains Framework (TDF)1 can be used to
understand HCPs’ behaviour; key domains may be
mapped to Behavioural Change Techniques (BCTs)
which are considered ‘active components’ of an interven-
tion.
This qualitative study aimed to explore general prac-
titioners’ (GPs’) and community pharmacists’ views of
medicines management in PWD, their approach to pre-
scribing and dispensing for these patients, and their per-
ceptions of barriers and facilitators to successful
medicines management for PWD, using a theory-based
approach.
Face-to-face interviews were conducted between
October 2015–March 2016. GPs were recruited from a
purposive sample of ten practices across Northern Ire-
land. Pharmacists were sampled from community phar-
macies which dispensed >75% of prescriptions from the
aforementioned practices. Written informed consent was
obtained prior to commencing data collection. Each
semi-structured interview used a topic guide based on
the 14-domain TDF1. All interviews were digitally
recorded, transcribed verbatim, checked for accuracy
and anonymised. Data was analysed using NVivo 10.
Transcripts were analysed using both the framework
method (utilising TDF domains as coding categories)
and content analysis (to identify barriers and facilitators
to successful medicines management within each theoret-
ical domain). Ethical approval was obtained for this
study (15/EE/0103).
Thirty HCPs were interviewed to reach data satura-
tion (n = 15 GPs, n = 15 pharmacists). Interviews lasted
49 min on average. A holistic knowledge of patients’
personal and social circumstances was regarded as a
facilitator to successful medicines management by both
GPs and pharmacists, however pharmacists’ limited
access to patient records was felt to be a barrier to this
(‘Knowledge’ and ‘Environmental context and resources’
GPs felt they lacked confidence (‘Beliefs about capabili-
ties’) and awareness (‘Knowledge’) of dementia drugs
which are usually initiated in secondary care, manage-
ment of behavioural and psychological symptoms, and
pain. Whilst all aspects of medicines management (pre-
scribing, dispensing, conducting medication review,
monitoring adherence, counselling) were discussed by
participants, many remained concerned that they ‘lost
control’ over the medicines management process once
the PWD left the GP surgery/pharmacy (‘Beliefs about
consequences’). There was a clear disparity between GPs
and pharmacists with respect to conducting medication
review; whilst both HCP groups talked about the impor-
tance of this for PWD, each thought the other profes-
sional group should assume responsibility for it (‘Social/
professional roles and identity’) due to various work
environment-related barriers (‘Environmental context
and resources’).
This study has identified a number of barriers and
facilitators that may be targeted as part of an interven-
tion to improve medicines management for PWD. How-
ever, findings only reflect participants’ perceptions of
the influences on their clinical behaviour. Task group
workshops2 will be held with HCPs to obtain their input
on pragmatic intervention development and mapping of
key theoretical domains to BCTs, followed by a small
feasibility trial of the intervention.
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Evaluating pharmacy interventions
targeted to people affected by
dementia: a systematic review of
identified interventions to inform the
development of a new community
pharmacy tool
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One of the recommendations within the recent review of
community pharmacy in England [1] is the development
of chronic disease management services. People with
dementia, which is a chronic life limiting disease, may
benefit from such a service. Medical Research Council
guidance on the development and evaluation of complex
interventions is to firstly undertake a systematic review
of the relevant literature.
The aim of this review is to identify and evaluate tri-
alled interventions aimed towards patients affected by
dementia that utilise a member of the pharmacy team.
The PICOS (Population, Intervention, Comparator,
Outcome, Setting) method was used to set the inclusion
criteria, as suggested by Cochrane [2]. Studies were
included if there was a pharmacy team member with a
key role in the intervention, there was a ≥70% preva-
lence of dementia and the research was completed.
Sources searched included Ovid MEDLINE, EMBASE,
CINAHL, Opengrey, NHS evidence and the references
of included studies. Two researchers screened indepen-
dently, then discussed disagreements. Studies were qual-
ity assessed based on the GRADE approach also
recommended by Cochrane [2] and consisted of each
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study being rated from high to very low taking into con-
sideration a number of elements such as study design,
limitations (and risk of bias) and imprecision.
The total records identified from all sources was 1120
which led to a total of 29 studies being included in this
review. There were 21 service evaluations, 3 cross-sec-
tional studies, 2 case studies, 1 audit, 1 randomised con-
trolled trial and 1 non-randomised intervention study
with five being set in community pharmacy. Sixty nine
percent of the interventions were medication related
which included medication reviews and the discontinu-
ing of targeted medicines such as antipsychotics, benzo-
diazepines and anticholinergics. Other interventions
included memory screening services and the education
of patients or staff. Twenty four of the interventions
involved other healthcare professionals and 26 studies
were graded as low or very low quality largely due to
observational study designs.
This review identifies a variety of interventions which
could be utilised in a community pharmacy setting for the
benefit of people affected by dementia. Although a limita-
tion to this review was that several conference abstracts
were included (which led to minimal information being
able to be extracted), this reinforces the message that lim-
ited research has currently been conducted within this
field and more robust research needs to be performed.
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Withdrawing antidementia medications
in advanced dementia: an analysis of
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online chat forum
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Considerable uncertainty exists surrounding if, how and
when to discontinue treatment with antidementia drugs,
particularly as dementia progresses and patients
approach end of life [1, 2]. Experiences of informal care-
givers of people with advanced dementia after with-
drawal of antidementia medications are unknown.
The aim of this study was to investigate the expe-
riences of informal caregivers of people with
advanced dementia when antidementia medications
(acetylcholinesterase inhibitors and/or memantine)
were stopped. Study objectives were to systematically
search the discussion threads and posts of the online
Talking Point discussion forum, hosted by the
Alzheimer’s Society for anyone affected by dementia,
to explore the experiences of carers and family mem-
bers of people with advanced dementia when antide-
mentia medications are withdrawn.
Qualitative analysis of archived discussion threads
and posts of the Talking Point online forum. All
archived threads between 2005 and February 2017 were
searched using combinations of the following search
terms: ‘cholinesterase inhibitor(s)’, ‘acetylcholinesterase
inhibitor(s)’, ‘donepezil’, ‘rivastigmine’, ‘galantamine’,
‘memantine’, ‘NMDA antagonist’, ‘withdrawal’, ‘discon-
tinuation’, ‘removal’ ‘cessation’, ‘deprescribing’, ‘drug
holiday’, ‘advanced dementia’, ‘dementia’, ‘drug with-
drawal’, ‘medication withdrawal’, and ‘drug guidance’.
This yielded 95 relevant threads which were analysed
thematically using the Framework Method. The School
of Pharmacy Ethics Committee, Queen’s University Bel-
fast, granted ethical approval for the study and Alzhei-
mer’s Society granted permission for use of archived
discussions from the Talking Point website.
Seven key themes emerged from data analysis: (1)
opinions of others including healthcare professionals,
family, friends or other Talking Point members; (2)
method of withdrawal (weaning versus immediate with-
drawal); (3) no change in clinical condition upon with-
drawal; (4) improvement in clinical condition upon
withdrawal; (5) worsening in clinical condition upon
withdrawal; (6) complexity/uncertainty regarding change
in clinical condition following withdrawal; and (7) the
effect of medication withdrawal on caregivers.
The strength of this study lies in the analysis of an
online chat forum, representing an innovative form of
data collection from what can be considered to be a
large, naturally occurring, floating focus group and
offering an unusual opportunity to tap into public opin-
ion as it formed. Limitations must be considered in
interpreting the study findings; one website was anal-
ysed, and those who posted on the Talking Point forum
may represent a biased subset of the caregiver popula-
tion. Generalisability or transferability to a wider popu-
lation cannot be assumed.
The emergent themes highlighted the value caregivers
ascribed to the advice and experiences of healthcare pro-
fessionals, family, friends or other Talking Point mem-
bers, concern regarding the method of withdrawal of
antidementia medications, the varying consequences of
withdrawal on their loved one’s clinical condition, and
uncertainty regarding the benefits and consequences of
stopping antidementia medications. These findings
emphasise the need for patient-centred, highly individu-
alised treatment and further research into the with-
drawal and optimal use of antidementia medications.
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The activities of clinical pharmacists in hospitals are
described under the umbrella term pharmaceutical care,
which is a model of pharmacy practice where pharma-
cists work in partnership with patients and other health
and social care professionals to achieve optimal out-
comes with medicines.
The research aims to understand what hospital clini-
cal pharmacists perceive to be suboptimal pharmaceuti-
cal care in the context of their own practice.
For the purpose of this research, pharmaceutical care
was described to participants as being a continuum,
ranging from harm ?suboptimal ?optimal.
A qualitative approach was adopted, using focus
groups [1]. Participants were recruited by email sent to
all hospital clinical pharmacists within the division (5
hospital pharmacies). Ethical approval for the research
was obtained. All research participants consented to
their inclusion in the study. Each focus group of 3–5
hospital clinical pharmacists lasted 55–65 min, and was
audio recorded to provide context to the output if
needed. Reflective accounts were kept by the PI and
facilitator. Each group were given post-it notes to docu-
ment their responses to the question “what would sub-
optimal pharmaceutical care look like”, using the
patient-focussed pharmaceutical care activities of medici-
nes reconciliation and medicine/Kardex review.
Prompts were provided using the headers of team,
task, individual, and policies and procedures, used in
quality improvement methodologies. The responses will
be mapped to the theoretical domains framework [2]
during data analysis.
A total of 22 participants took part. The majority
were female (n = 16). A total of 78 ideas on the theme
of suboptimal pharmaceutical care were generated and
written onto post-it notes; the majority were for the
topic of medicines reconciliation (n = 45). This output
was exemplified for suboptimal pharmaceutical care in
medicines reconciliation by statements like “incomplete”
and “using wrong/out of date sources”, and for medici-
nes review by statements like “time pressures” and “ac-
cess to computer”.
Focus groups generated ideas and themes for subop-
timal pharmaceutical care in medicines reconciliation
and medicines review. The focus group setting may have
hindered the disclosure of personal accounts of subopti-
mal pharmaceutical care. This will be addressed by
future work with in-depth one-to-one interviews with
hospital clinical pharmacists.
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Patient safety is at the forefront of clinical pharmacy
services. Current financial pressures within the NHS
have led pharmacy teams to devise new, more efficient
methods to prevent patient harm. One approach is the
development of acuity tools to identify patients at most
risk of harm from medicines and the targeting of phar-
macy services to those patients who would most benefit.
However, such service developments are rarely formally
disseminated and little is known about acuity tools in
practice
The aim of this study is to understand current prac-
tice regarding the use of pharmaceutical care acuity
tools in UK hospital pharmacy services.
University research ethics approval was obtained in
June 2017. A national survey was circulated to chief
pharmacists of acute NHS hospitals in the UK to eluci-
date whether hospital pharmacies had adopted mecha-
nisms for prioritising patients. Where such mechanisms
exist, respondents were asked to participate in a 30 min
semi-structured telephone interview exploring the devel-
opment, evaluation and application of their tool. Partici-
pants were also asked to share any relevant
documentation. Documents were analysed using docu-
mentary analysis by organising information such as ‘risk
factors’ into categories related to acuity assessment and
levels. Interviews were transcribed verbatim and themat-
ically analysed.
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To date, 78 out of 169 acute trusts in the UK
responded to the online survey (46% response rate).
Thirty-six interviews were conducted. The majority of
tools had been developed in-house or adapted from
other trusts and had not been evaluated. Preliminary
findings show that current tools are often a combination
of pharmacy service prioritisation (such as identifying
patients who require medicines reconciliation) and
patient acuity (based on the complexity of their condi-
tion and medication use). Communication with the
inter-professional team, application of the pharmacists’
clinical judgement and local context were described as
key to the appropriate use of acuity tools.
Interviewees discussed the benefits of acuity tools
including enhanced continuity of care and workload pri-
oritisation. The ability to risk-assess and stratify patients
based on a set criteria instilled confidence in pharmacists
by ensuring that they would not ‘miss’ high risk
patients. Furthermore, tools facilitated the management
of pharmacy service resources by providing surveillance
of service demand.
Potential disadvantages of tools included the sensitiv-
ity of acuity tools on wards which commonly use high
risk medicines and the potential for rigid application of
tools without professional judgement. In addition, phar-
macists were not clear on their legal stance if patients
were selected as a priority, but were not seen by a phar-
macist due to shortage in staff or lack of time. Pharma-
cists also believed allocating high acuity levels to
experienced pharmacists might lead to the de-skilling of
junior pharmacists.
Acuity tools were seen to be useful for prioritising
workload and ensuring the right patients are seen at the
right time. However, they are not without their limita-
tions and few trusts had formally evaluated their acuity
tools. In order to address this limitation, future work
will include the systematic development and evaluation
of an acuity tool, grounded in evidence and practice.
A quality improvement project
addressing peri-operative medication
reconciliation and administration in
elective surgical patients using five or
more medications pre-admission
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Medication reconciliation is recommended at care tran-
sitions. Little is known about the rate of unintentional
discrepancies or missed doses at elective surgical admis-
sion.
This study sought to quantify the rate of uninten-
tional discrepancies and clinically inappropriate missed
doses, and to apply quality improvement (QI) methods
to reduce these rates, at elective surgical admission of
patients using ≥5 medications pre-admission.
This study combined QI with an observational study.
A multidisciplinary QI team was assembled. Following
Deming’s System of Profound Knowledge,[1] Plan-Do-
Study-Act (PDSA) and Langley’s Model for Improve-
ment,[2] a QI project was undertaken, employing stan-
dard QI techniques: weekly meetings held to brainstorm;
process map; set goals; generate, appraise and apply
tests of change, review measurement of goal attainment.
A prospective observational study was employed to
measure rates (Study) of: (1) unintentional discrepancy
(UD) (2) clinically inappropriate missed doses (CIMD).
The sampling frame was adults using ≥5 medications,
scheduled for surgical admission who attended the pre-
assessment clinic (PAC). Patients were randomly
selected. The investigator took a best possible medica-
tion history, performed medication reconciliation,
reviewed the prescription and administration chart and
identified UDs and CIMDs. UDs were confirmed as
unintentional by consultation with clinicians. CIMDs
were assessed for potential to cause harm.[3] Rates of
UD and CIMD were analysed using statistical process
control (SPC) to identify variation. This enabled the
plotting of run charts to display weekly rates of UD
and CIMD. Findings were fed-back to the team
weekly1. Research ethics approval was granted by the
study hospital.
Over 20 weeks, 140 patients were recruited. Patients
used median 8 (range 5-20) pre-admission medications,
median age 61 (range 19-91), half (51%) were male.
Agreed goals were absence of UD and CIMD. Applied
tests of change (Plan and Do) included: 1) [Week 4]
Design of, with patient involvement, a My Medicines
Form with instructions to record a pre-admission medi-
cation list. This was posted to planned admissions; 2)
[Week 14] Design of a multidisciplinary medication rec-
onciliation form for use during PAC and anaesthetic
review; 3) [Weeks 10-20] Training PAC nurses to under-
take comprehensive medication history taking. Non-
applied changes were deployment of pharmacist to Day
of Surgery Admission (DOSA) lounge and use of mobile
text message reminders to patients. Data were collected
regarding UD on all 140 patients, and CIMD for 121
patients commencing week 4. Some 65% of patients
experienced ≥1 UD by 24 h after admission (weekly rate
range 36-85%). 79% (weekly rate ranged 50-100%)
experienced ≥1 CIMD by 24 h after admission, the
majority (90%) minor, 10% moderate, none severe. SPC
identified no evidence of variation for either outcome
over the study period, indicative that no improvement
had occurred.
UD and CIMD were commonly experienced. QI
should continue (Act). A weakness was the short dura-
tion (20 weeks), which potentially limited observation of
any change effect, because the lag time between PAC
and admission may be months. Small sample sizes lim-
ited reliability of analysis. Complementary qualitative
research may support improvement.
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